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Throughout most of this text, serum phenobarbitone
concentration measurements are reported in the
locally popular ~g.ml-1 units and not in the SI
units of mmol.1-1 • The relevant conversion factor
for ~g.ml-1 to mmol.1-1 is 5.55.
-xiii-
INTRODUCTION
Practicing clinical veterinarians in large companio~ animal prac-
tices are often faced with the phenomena of epileptic seizures
which occur commonly in dogs. The high incidence of non-
responsive cases is often frustrating, and the literature offers
incomplete, conflicting and often inaccurate information. The
concept of therapeutic anti-epileptic drug concentration monitor-
ing, as applied in man as an aid to treatment, appears attractive
in order to provide an improved service to the patient and
client.
An investigation into the pharmacokinetics of phenobarbitone,
particularly at steady state, became necessary in order to inter-
pret the application of drug serum concentration monitoring. The
trend of veterinarians to extrapolate human kinetics to dogs is
common and unsound. This study was an attempt to identify the
similarities and dissimilarities between the pharmacokinetics of
dogs and humans.
No literature was available, both for man or animal, on the ef-
fect of food on the absorption of phenobarbitone. As dog owners
frequently have to administer oral medication in food, this was
an important factor to examine.
The kinetics of the drug was determined in a group of epileptic
dogs in order to provide a possible base-line therapeutic regime
on commencement of treatment, and the practical application of
therapeutic drug monitoring in order to individualize and improve
response to treatment was explored.
j
Chapter One
Phenobarbitone - Pharmaceutical Chemistry, Mechanism of Action,
Pharmacology, Toxicity and Pharmacokinetics.
1.1 PHARMACEUTICAL CHEMISTRY
1.1.1 Structure and Solubility
Fig.1 Structure
(phenobarbitone)
of 5-ethyl-5-phenyl barbituric acid
Phenobarbitone Sodium, USP (soluble phenobarbitone, Luminal
sodium), was the second barbituric acid derivative of clinical
importance to be developed. It was synthesized in 1912 in Germany
by HAUPTMANN and patented under the name of Luminal. It is a
white crystalline material with a somewhat bitter taste. The
molecular weight is 232.23, and the melting point is 176°C
(Johannessen,1989).
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The free acid is only slightly soluble in water, whereas the
sodium salt is freely soluble (Booth,1988; Schafer,1985; Johan-
nessen,1989). Phenobarbitone is soluble in organic solvents such
as chloroform, diethyl ether, and ethanol. The partition coeffi-
cient between chloroform and water is 4.2 at pH 3.4 (Johannessen,
1989). The pKa is 7.3 and it is a stronger acid than other bar-
biturates (Rimmer and Richens,1988; Johannessen,1989). These
acidic properties are important in relation to the distribution
and excretion of the drug. The pKa of phenobarbitone is such that
a change of extracellar pH without a corresponding change of
intracellular pH will cause a shift of the drug from one compart-
ment to the other.
1.2 MECHANISM OF ACTION
In humans, phenobarbitone is effective against generalized tonic-
clonic seizures and partial seizures but has very little effect
in absence seizures. All the different barbiturates are not
equally effective as antiepileptic drugs in ambulatory patients
with epilepsy. The sedative-anaesthetic barbiturates, such as
pentobarbitone, produce marked sedation at anticonvulsant doses,
whereas phenobarbitone is clinically useful because it has an-
tiepileptic activity without causing excessive sedation (Rimmer
and Richens,1988).
Although phenobarbitone has been extensively studied in humans,
its basic mechanisms of selective antiepileptic action are not
yet fully understood (Prichard and Ransom,1989). Earlier workers
proposed several mechanisms that seemed plausible in light of the
data then available, but the more recent advance of neurobiologi-
cal knowledge has rendered most of the older theories improbable.
Some are still quoted in recent literature:
The antiepileptic effects of phenobarbitone are prob-
ably the results of at least two mechanisms. Decreased
monosynaptic and polysynaptic transmission which
presumably results ln reduced neuronal excitability.
Also, the motor cortex's threshold for electrical
stimulation is increased (Shell, 1984).
* The mechanism of action of the benzodiazepines and the
barbiturates is thought to be the facilitation of
chloride-ion transport through postsynaptic neuronal
cell membranes (Rimmer and Richens,1988).
* Presynaptic action to reduce calcium entry into the
neurons and block neurotransmitter release (Rimmer and
Richens,1988).
* Non-synaptically to reduce voltage dependent sodium and
potassium conductances and block repetitive firing
(Rimmer and Richens,1988).
Although current knowledge of epileptic pathophysiology has ad-
vanced considerably, the chain of events that occur from cellular
defect to clinical seizure is still too vaguely defined and
therefore, the point in this chain where the critical action of
antiepileptic drugs occur remains obscure.
Recent evidence points toward modulation of the inhibitory
postsynaptic actions of gamma-aminobutyric acid (GABA) and the
excitatory postsynaptic actions of amino acids, such as
glutamate, as key phenobarbitone-sensitive phenomena relevant to
seizure control (Prichard and Ransom,1989).
1.2.1 Action of phenobarbitone on abnormal phenomena
In experimental animals phenobarbitone elevates electroshock
seizure threshold and protects against pentylenetetrazol-induced
convulsions more effectively than phenytoin does (Prichard and
Ransom,1989). This phenomena could imply that phenobarbitone has
some property not shared with phenytoin that causes elevation of
threshold to electrical and chemical epileptic stimuli.
cannot be a selective effect on abnormal nervous tissue, because
elevated thresholds can be demonstrated in normal animals
(Prichard and Ransom,1989). In work done by Aston and Domino
(1961), it was determined in the monkey that pentobarbitone
equally raised the motor cortical and reticular formation after-
discharge thresholds. However, phenobarbitone raised cortical
threshold more than the reticular threshold, and phenytoin raised
only the cortical threshold. These findings seem quite consistent
with the relative antiepileptic and hypnotic potencies of the
three drugs. The depression of consciousness, elevation of
thresholds for electrical and chemical seizures, and production
of EEG fast activity, all of which distinguish phenobarbitone
from phenytoin, therefore could all be related to actions in the
reticular formation. Further studies are required to extend their
results and to move toward a cellular explanation of them
(Prichard and Ransom,1989).
Comparisons of phenobarbitone and pentobarbitone in a different
study showed phenobarbitone to be .more potent against after-
discharges in isolated cortex and the interictal spikes in hip-
pocampal slices exposed to penicillin (Vazquez et al,1975). This
study also included phenytoin, which was substantially less
potent than phenobarbitone, and diazepam, which was very slightly
more potent. A study on rabbits showed that phenobarbitone in-
hibited spread of abnor~al activity from the focus to adjacent
cortex and diencephalon and suppressed the firing of the focus
itself. Phenytoin was a better inhibitor of cortical spread but
had no effect on the focus or on spread to the diencephalon
(Morell et al,1959).
The above data suggests that phenobarbitone exerts an important
part of its antiepileptic action on abnormal neurons, in contrast
to phenytoin which may act primarily on normal neurons. This has
not been proven, and the cellular basis for the difference is
. unknown (Prichard and Ransom,1989).
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1.2.2 Actions of phenobarbitone on normal phenomena
Extraneural Tissues
Enzyme induction is the only well-defined barbiturate action out-
side the nervous tissue that has received attention as a possible
antiepileptic mechanism. It has been shown in numerous studies
that barbiturates cause increased synthesis and concentration of
a number of enzymes in a variety of tissues. Phenobarbitone lS
the most effective inducer among them, but whether this is re-
lated to any property also important for its antiepileptic
potency is not known. The most thoroughly studied inductions are
of hepatic microsomal enzymes, several of which have been impli-
cated in barbiturate toxicity (Prichard and Ransom, 1989;
Booth,1988). One author has proposed that some antiepileptic
drugs, including phenobarbitone, act against seizures because
they alter folate metabolism; the mechanisms are not completely
understood but may involve hepatic enzyme induction
(Reynolds,1973).
The relevant data as a whole does not provide strong support for
this theory but does prompt reflection on the possibility that
what antiepileptic drugs do in the rest of the body may influence
what they do in the brain. At present, however, there is no good
evidence to suggest that enzyme induction or any other ex-
traneural action of phenobarbitone is responsible for its an-
tiepileptic activity.
Sleep and Anesthesia
Barbiturates have been used to cause sleep more frequently than
for any other purpose. The exact mechanism of their sedative ac-
tion is not known, but it is known that the state they produce is
not equivalent to physiological sleep. Total time spent in the
rapid eye movement phase of sleep lS reduced and rebounds after
barbiturate use is stopped (Prichard and Ransom,1989). Since all
barbiturates and many quite different drugs have similar effects,
it seems unlikely that clues to the selective antiepileptic ac-
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tion of phenobarbitone will be found ln the mechanisms by which
it can cause sleep.
Electroencephalogram and Evoked Potentials
Most barbiturates appear to exert quite similar actions on the
EEGs of man and common experimental animals, although their
potencies and durations of action vary greatly. Electroen-
cephalogram power spectrum analysis has revealed some differences
among barbiturates, but these have not been shown to correlate
with antiepileptic potency (Prichard and Ransom,1989). These
authors also report that evoked potential studies, like those on
the EEG, have so far shown no selective effect of antiepileptic
barbiturates. In general, barbiturates depress nonspecific and
neospinothalamic sensory-evoked potentials at doses that spare or
enhance other specific ones. Further, a study done on the dif-
ferences between antiepileptic concentrations of phenobarbitone
and phenytoin at several sites in the cat brain, showed the
mesencephalic reticular formation to be most sensitive to
phenobarbitone. There is no evidence at present that any aspect
of barbiturate antiepileptic action depends on the mesencephalic
reticular formation, but experiments likely to detect such depen-
dency have not been done (Prichard and Ransom,1989).
Synaptic Transmission
The most potent neuropharmacological actions of barbiturates yet
demonstrated are on synaptic transmission or phenomena related to
it. Some of its synaptic actions occur at concentrations as low
as 25 ~M, which is well within the range of concentrations found
in the serum of patients whose seizures are controlled by the
drug. These actions are the possible basis of phenobarbitone's
antiepileptic effectiveness (Prichard and Ransom,1989).
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The concentration of free phenobarbitone in serum correlates bet-,
ter with seizure control than does total concentration. About 40%
of serum phenobarbitone is protein-bound. The therapeutic range
of free phenobarbitone concentration is 25 to 100 ~M.1-1
(6-24 ~g.ml-1). In human's, free phenobarbitone concentrations
greater than 100 ~M.1-1 frequently produce sedation, and still
higher concentrations produce anaesthesia. It is not known
whether these clinical effects of high phenobarbitone concentra-
tions are due to a more pronouced effect of the same mechanisms
that are responsible for the drug's antiepileptic action, or to
different ones (Prichard and Ransom, 1989).
1.3 PHARMACOKINETICS
1.3.1 Absorption
The majority of orally administered phenobarbitone is absorbed in
the small intestine due to the extensive surface area and ample
time for absorption. Studies in man have shown that after oral or
intramuscular administration, peak plasma concentrations occur
within 2 to 12 hr, and are linearly related to dose within a wide
range of doses. The average time to peak plasma concentrations is
2 hr after oral dosing, but the peak may be considerably delayed
in patients with diminished gastrointestinal motility or poor
circulation (Rust and Dodson,1989).
In a study on dogs, peak serum concentrations were observed at
3.2 t 1.0 hr (Ravis et al,1984).
Phenobarbitone has a high bioavailability in adults after oral or
intramuscular administration. studies in dogs and humans have
shown 80% to 100% absorption of orally administered phenobar-
bitone (Rust and Dodson,1989; Pedersoli et al,1987; Gallagher and
Freer, 1985 )
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Gastric absorption of sodium phenobarbitone is enhanced if it is
dissolved prior to administration. The presence of food and
neutralizing agents or rapid gastric emptying slows phenobar-
bitone absorption, and the presence of even small amounts of
ethanol in the stomach or blood accelerates gastric absorption
(Rust and Dodson,1989).
The role of enterohepatic circulation in phenobarbitone phar-
macokinetics is incompletely characterized. Several studies have
demonstrated unmetabolized phenobarbitone in bile within 1 hr of
intravenous administration. Biliary phenobarbitone concentration
has also been found to be twice the peak serum concentration
(Rust and Dodson,1989).
1.3.2 Distribution
Phenobarbitone disseminates into all body tissues. Lowering serum
pH increases the non-ionized portion in serum, enhancing diffu-
sion into tissue, whereas higher serum pH has the opposite effect
(Rust and Dodson,1989).
Phenobarbitone binding to plasma proteins (~ 45%) plays a minor
role in distribution. Binding is readily reversible and indepen-
dent of drug concentration, ionic dissociation, and serum calcium
concentration (Rust and Dodson,1989; Rimmer and Richens,1988).
This relatively low degree of protein binding means that the drug
is less susceptible to alterations in plasma protein concentra-
tions and is unlikely to be significantly involved in drug inter-
actions in which there is competition for binding sites (Rimmer
and Richens,1988).
Concentrations of phenobarbitone in CSF of adults are 43% to 60%
of plasma concentrations and correlate well with the unbound
phenobarbitone concentration in serum. The CSF levels in infants
are similar, ranging from 48% to 83% of plasma levels (Rust and
Dodson,1989). The phenobarbitone concentration in CSF provides a
reliable index of phenobarbitone concentration in the brain.
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Under nonequilibrium dosing conditions, actions of phenobarbitone
correlate better with CSF levels than with either dose or the
rate of drug administration. It has been shown that the loss of
righting reflex in rodents is related to CSF concentrations and
is independent of either the dose or the rate of administration
(Rust and Dodson,1989).
Phenobarbitone concentrations are higher in CSF than saliva, a
more acidic but similarly low-protein fluid. The concentration ln
saliva is, however, sensitive to pH changes and it is therefore
unwise to use saliva for serum drug level monitoring for
phenobarbitone(Rimmer and Richens,1988).
After intravenous administration, the distribution of phenobar-
bitone into body organs has two phases. The early phase involves
distribution to highly vascular organs including liver, heart,
and kidney, but not the brain, muscle, or intestine. During the
late phase, phenobarbitone achieves fairly even distribution
throughout the body except for relative exclusion from fat. This
pattern of relatively slow entry into brain and limited distribu-
tion into fat is related to phenobarbitone's low lipid
solubility, as drugs with higher lipophilicity rapidly enter
brain (Rust and Dodson,1989).
The relative exclusion of phenobarbitone from body fat should be
taken into consideration when dosages are based on weight to
avoid overdosing obese patients. The slow distribution into the
brain also makes phenobarbitone not an ideal drug for the treat-
ment of status epilepticus.
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1.3.3 Volume of Distribution
In dogs, the relative volume of distribution (Vd) of phenobar-
bitone is 0.7 ± 0.151 l.kg- 1 after an oral dose of 5.5 mg.kg-
1
and 0.689 ± 0.136 1.kg-1 after an oral dose of 15 mg.kg-
1
(Pedersoli et al, 1987). In a similar study, the Vd was found to
be 0.7436 ± 0.698 l.kg- 1 after oral administration of 2 mg.kg- 1
daily for 5 days to dogs (Ravis et al,1984) •
. In adult humans, the relative volume of distribution ranges from
0.36 to 0.67 L.kg- 1 after intramuscular doses and from 0.42 to
0.73 1.kg-1 after oral doses. The average Vd for phenobarbitone
is larger in newborns, averaging approximately 1.0 l.kg- 1 • This
is probably the consequence of their relatively larger extracel-
lular fluid volume (Rust and Dodson,1989).
1.3.4 Metabolism and Excretion
In spite of decades of use and the introduction of other agents,
phenobarbitone has remained the most widely used antiepileptic
drug in the world. Although the main pathways of phenobarbitone
clearance have been identified, knowledge of its quantitative
disposition is based on a series of observations rather than
definitive studies. This is surprising in the light of recent ad-
vances in analytical and enzymatic techniques. Few studies have
been performed in the last few years and today there remains a
large discrepancy between the degree of investigation and the
degree of use. For example, phenobarbitone is widely used in
children but disposition in this population is virtually unknown.
Definitive quantitative investigations of phenobarbitone metabo-
lism are still warranted (Anderson,1989). The following metabolic
pathways have been studied and reported in various publications:
-10-
Excretion of Unchanged Phenobarbitone
Phenobarbitone is partly metabolized and partly excreted un-
changed in the urine (Shell,1984)". There would appear to be con-
siderable intersubject and intrasubject variability in the amount
of phenobarbitone excreted unchanged in the urine. studies by
numerous researchers and referred to by Anderson(1989J report
that the fraction of phenobarbitone excreted unchanged in the
urine range between 9% to 48% (average of 22-25%).
The renal clearance of phenobarbitone is dependent on both urine
flow and urine pH due to the lipophilicity and pKa of this drug
(Anderson,1989; Rimmer and Richens,1988; Gal1agher and
Freer, 1985; Booth,1988). This phenomena may explain some of the
intersubject variability found in the fraction of dose excreted
unchanged in the urine. After a drug is filtered by the
glomerulus and possibly actively secreted into the tubule, it may
be subject to passive reabsorption. Drug reabsorption takes place
primarily in the distal tubule where the tubule membranes favour
the transport of lipid-s9luble and unionized compounds. The effi-
cient reabsorption of water from the proximal tubule and Loop of
Henle results in a large concentration gradient between drug in
the distal tubule and drug in the plasma. Increasing urine flow
decreases this concentration gradient, resulting in a decrease in
passive reabsorption. Small changes in urine pH can cause large
increases/decreases in the percentage of an unionized weak acid,
like phenobarbitone, that is passively reabsorbed (Anderson,1989;
Booth,1988). Alkaninization of the urine increases the renal
excretion of unchanged phenobarbitone by reducing the non-ionic
back diffusion from the distal renal tubule to the plasma. This
property has been exploited in the treatment of phenobarbitone
overdosage. The renal clearance can be increased from 4-6





The major site of metabolism of phenobarbitone is in the liver.
Through microsomal enzyme action, it is hydroxylated in the para
position to form p-hydroxyphenobarbitone (PBOH) (Booth,1988; An-
derson,1989; Rimmer and Richens,1988; Shell,1984; Gallagher and
Freer,1985). This metabolite has weak anticonvulsant activity and
does not contribute significantly to the action of phenobarbitone
(Booth,1988; Rimmer and Richens,1988). A substantial fraction of
the PBOH is then conjugated with glucuronic acid to form PBOR
glucuronide. An earlier article written by Butler(1956) and
referred to by Gallagher and Freer(1985) state that PBOH may also
be conjugated with sulfate. This sulfate conjugate of PBOH has,
however, not been substantiated experimentally and may have been
due to problems in the analytical method (Anderson,1989).
N-Glucosidation
Recent research has proposed that l-(S-D-glucopyranosyl)
phenobarbitone is a quantitatively significant metabolite of
phenobarbitone. Thin-layer chromatography of urine identified the
N-glucoside conjugate of phenobarbitone after comparison to a
synthetic standard. Glucosidation may be a significant pathway in
the disposition of phenobarbitone in the neonate accounting for
50% of the drug and metabolites in the urine (Anderson,1989).
other routes of Metabolism
Epoxidation and Subsequent Reactions
The hydroxylation of phenobarbitone to PBOH is presumed to be
mediated by the cytochrome P-450 system. Cytochrome P-450-
mediated aromatic hydroxylation 1S postulated to occur through
epoxide intermediates. Due to the highly unstable nature of
epoxides, they can undergo spontaneous rearrangement to phenols
primarily in the para orientation. Theoretically, meta-
- , ? -
hydroxyphenobarbitone could also be formed. Meta-
hydroxyphenobarbitone has been identified by gas chromatography-
mass spectrometry (GC-MS) analysis as a minor metabolite in rats
and guinea pigs (Anderson,1989).
Aliphatic Hydroxylation
Due to steric hindrance, cytochrome P-450-mediated aliphatic
oxidation of the ethyl group of phenobarbitone is not a favoured
reaction. However, small amounts of 5(1-hydroxyethyl)5-
phenylbarbituric acid was detected by GC-MS analysis of the urine
of rats and guinea pigs. This metabolite has not been found in
human urine (Anderson,1989).
Hydrolysis
Phenobarbitone in aqueous solution is subject to spontaneous
hydrolysis to a greater extent than any of the dialkylbar-
biturates. The extent to which phenobarbitone is subject to
hydrolysis in the human body is unknown. Studies with 2_14C
phenobarbitone in mice and rats found only trace amounts of 14C-
labelled CO 2 in expired air. However, since there is still a sig-
nificant part of the phenobarbitone dose that is not accounted
for by excretion of unchanged phenobarbitone and metabolites,
this mode of elimination cannot be totally discounted
(Anderson,1989; Gallagher and Freer,1985).
Autoinduction
Phenobarbitone is regarded as the classic inducer of hepatic
microsomal metabolism. Anderson(1989) reports on two studies on
elimination rates of phenobarbitone in humans. Based on the
results the author concluded that phenobarbitone does not undergo
time-dependent changes ln total plasma clearance. An earlier
study of three volunteers suggested that the elimination rate may
actually decrease after prolonged dosing of phenobarbitone.





problems ln analytical methodology and the small number of sub-
jects.
In contrast to the results in humans, there is evidence in both
dogs and the rat that autoinduction occurs. During prolonged
dosing in the dog, the daily elimination rate increases and it is
suggested that autoinduction occurs, resulting in a decrease ln
phenobarbitone tts (Ravis et al,1984). In a study done on the
urine of two groups of Sprague Dawley rats by Anderson, there was
a significantly lower recovery of total radioactivity from the
administration of 14C-phenobarbitone in the induced group of rats
than the noninduced rats. The author concluded that this result
would be consistent with the effect of induction on metabolites,
but was also shown in another study ln the rat where biliary
excretion of PBOH resulted in a decreased fraction of the dose
metabolized to PBOH or excreted as phenobarbitone. The
metabolism of phenobarbitone involved is at this time
understood as only 40% to 50% of the phenobarbitone
rat has been isolated and identified (Anderson,1989).
1.3.5 Excretion
A number of factors contribute to the elimination of phenobar-
bitone. The phenobarbitone half-life is the longest among the
frequently used antiepileptic drugs. Phenobarbitone elimination
is slowed when liver metabolism or renal clearance is reduced, or
in the case when urine is rendered more acidic.
As previously discussed, phenobarbitone is eliminated from the
body both by hepatic metabolism and by renal excretion. In the
liver, phenobarbitone is parahydroxylated and subsequently con-
jugated to glucuronic acid. Both unmetabolized and parahydroxy-
lated phenobarbitone are excreted in urine. Enterohepatic cir-
culation and faecal excretion are not regarded as important con-






Phenobarbitone elimination has first-order kinetics and thus the
fraction of drug removed is independent of concentration
(Pedersoli et al.,1987; Ravis et al.,1984; Rust and Dodson,1989).
In humans, from 11% to 50% of phenobarbitone is eliminated from
the body per day corresponding to a half-life range of 24 to 140
hr. Average half-lives after single doses range from 75 to 126 hr
and are not influenced by route of administration. However, the
rate of urine flow and urinary pH do influence the phenobarbitone
elimination rate (Rust and Dodson,1989).
pH and flow influence phenobarbitone reabsorption in
nephron. Under usual circumstances total renal
phenobarbitone ranges from 0.7 to 8.8 ml.kg- 1 .hr-1
(Rust and Dodson,1989). This is much less than the
glomerular filtration rate, indicating extensive reabsorption in
the nephron. In a study on healthy dogs following single IV or
oral administration at two dosage rates, the mean total clearance
was 5.60 ± 2.31 and 6.66 ± 0.78 ml.kg- 1 .hr- 1 for doses of 5 and
15 mg.kg- 1 , respectively (Pedersoli et al., 1987). In an earlier
study, where phenobarbitone was administered orally 3 times a day
to healthy mature dogs at a dose of 2 mg.kg- 1 , total body
clearance was found to be 10.38 ± 4.68 ml.kg- 1 .hr-1 (Ravis,1984).
Frey et al.(1985J measured renal clearance of phenobarbitone
after intravenous administration of a single dose of phenobar-
bitone in beagle and mongrel dogs. Beagles were found to have a
clearance rate of 13.0 ± 1.7 ml.kg- 1 .hr-1 while that for
mongrel dogs was 7.0 ± 1.3 ml.kg- 1 .hr-1 • The differences were
statistically significant and related to different phar-
macokinetic models in these dogs.
The phenobarbitone half-life varies with age in humans. It is
longest in premature and full-term newborns who have similar
values typically ranging from 43 to 404 hr, and shortest in
children ranging from 37 to 94 hr.
In the dog, phenobarbitone (2 mg.kg- 1 ) administered orally 3
times a day for 5 days resulted in an elimination half-life be-
tween 37 and 75 hrs the mean elimination half-life was 53 ± 15
- 1 t;-
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hrs (Ravis et al.,1984). In the study done by Pedersoli et al.
(1987) following single IV and oral administration to dogs at 5
and 15 mg/kg, the mean elimination half-life was found to be 92.6
± 23.7 and 72.3 ± 15.5 hrs, respectively. No studies have been
done on the variation of the half-life with age in animals.
Epilepsy and therefore its control is, however, a rare occurrence
in young animals and such a study may not be justified.
1.3.6 Concentration-Effect Relationship
Although studies examining the relationship between plasma levels
of phenobarbitone and seizure control have produced conflicting
results, it would appear that plasma phenobarbitone levels
greater than 42 ~mol.1-1 are associated with improved clinical
efficacy. With plasma levels over 172 ~mol.I-1 the additional
therapeutic benefits decline and there is a higher incidence of
adverse effects (Rimmer and Richens,1988). It is well recognized
both in man and in dogs that tolerance occurs to the sedative ef-
fects of the drug so that a serum level of 20 ~mol.I-1 produced
acutely may have a greater sedative effect than a level of
200 ~mol.I-1 which has been maintained chronically (Shell,1984).
A therapeutic range of 42-170 ~mol.1-1 has been suggested as a
guide to therapy (Rimmer and Richens,1988).
1.4 TOXICITY
Worldwide use of phenobarbitone for almost a century has allowed
the accumulation of considerable knowledge of its toxicity.
Phenobarbitone enjoys a reputation of safety because serious
systemic side effects are very uncommon. Neurological and
psychological toxicity is, however, frequent.
1.4.1 Neurotoxicity
With the long-term usage of phenobarbitone, even the usual
dosage-producing serum concentrations of the drug in the broad
therapeutic range of 42 to 170 pmol.1- 1 , adverse changes in af-
fect, behavior, and cognitive function are often encountered in
the human patient. High serum concentrations cause neurological
signs of "drunkenness", including nystagmus, dysarthria, incoor-
dination, and ataxia. Often, the neurotoxic side effects occur
together in different degrees and have been reported in both man
and animals (Mattson and Cramer,1989; Shell,1984).
Sedation
Sedation would appear to be the major side effect of phenobar-
bitone. Complaints of fatigue and tiredness are difficult to
quantify and are often variable and subtle. The patient and
family may describe listlessness or lack of spontaneity even when
excessive sleeping time is not observed. As the dosage is in-
creased, overt sleepiness is observable and often apparent by
difficulty in arousal in the morning and naps after school or
work. Patients, however, complained of sedation for the first few
days of treatment which clears rapidly as tolerance develops
(Mattson and Cramer,1989).
Neurological Side Effects
Increasing the dosage of phenobarbitone eventually leads to
neurological signs similar to those found with the use of other
antiepileptic drugs. Dysarthria, incoordination, ataxia, dizzi-
ness, and nystagmus appear as serum levels exceed 170 pmol.1- 1
(Mattson and Cramer,1989). Side effects of sedation and ataxia





Instead of the sedative effect of phenobarbitone common in
adults, in children, and the elderly a paradoxical effect of the
drug may produce insomnia and hyperkinetic activity. Phenobar-
bitone has also been reported to exacerbate aggressiveness and
overactivity. The pattern of behaviour included signs of distrac-
tibilty, shortened attention span, fluctuation of mood, and ag-
gressive outbursts. The incidence in children was higher in boys.
Behavioural disturbances are more likely to become evident in
children in the presence of organic brain disease or deficits.
These behavioural disturbances have not been reported in animals
receiving phenobarbitone therapy.
character
Phenobarbitone therapy can produce an alteration in the character
of the patient and in particular can cause depression. It is dif-
ficult to determine whether such mood changes are a reaction to
the often newly diagnosed illness, the addition of another drug
to treat severe seizures, or a direct neurotoxic effect of
phenobarbitone. Clinical observations suggest a direct effect of
phenobarbitone, because changes to carbamazepine therapy have
been associated with improved mood scores (Mattson and
Cramer,1989) •
Cognition
A side effect of _phenobarbitone of considerable importance, espe-
cially in children, is a possible disturbance in cognitive func-
tion. Problems with memory or compromised work and school perfor-
mance may develop independent of sedation and hyperkinetic ac-




Frank overdosage of phenobarbitone causing serum levels in excess
of 200 ~mol.1-1 leads to progressive neurological dysfunction
and depression in levels of consciousness, even in patients on
long term therapy. Excessively high doses first cause ataxia,
dysarthria, nystagmus, incoordination, and uncontrolled sleepi-
ness. As the serum levels rise further, these effects progress to
stupor and coma. Ultimately, depression of cardiorespiratory
function may lead to death (Mattson and Cramer,1989).
In the mouse, orally administered phenobarbitone has a median
neurotoxic dose (LO so ) of 51 mg.kg-1 • Subcutaneous administration
increases the LOso to about 100mg.kg-1 • In the rat comparable
LOso values are 35 mg.kg-1 p.o. and 90 mg.kg- 1 s.c. The rabbit is
identical to that for the rat, while the cat is more sensitive to
phenobarbitone, with a LO so of 5 mg.kg- 1 (Gallagher and
Freer,1988).
Dependence, Habituation, and Withdrawal
Physical dependence on phenobarbitone occurs and abrupt discon-
tinuation after high dosage produces abstinence symptoms, includ-
ing anxiety, insomnia, tremors, confusion and seizures. These
symptoms can be reversed by reinstituting the drug. If a decision
is made to stop phenobarbitone therapy, it must be tapered off
very slowly to avoid withdrawal seizures (Mattson and
Cramer,1989; Rimmer and Richens,1988).
A neonatal withdrawal syndrome has been described in infants born
to epileptic mothers taking phenobarbitone. Phenobarbitone can
cross the placenta and enter the foetal system, and therefore
special care must be taken during the neonatal period of children
born to mothers who received phenobarbitone. The rate of
phenobarbitone elimination in neonates is probably slower than ln
adults, possibly because neonatal liver is not fully capable of
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metabolizing barbiturates until enzyme induction has occurred
(Mattson and Cramer,1989).
Some evidence suggests that discontinuation of phenobarbitone in
epileptic patients may lead to an exacerbation of seizures not
only because of the underlying epilepsy but also because of an
additional barbiturate withdrawal mechanism (Mattson and
Cramer,1989).
1.4.2 Long-Term Developmental Effects
Phenobarbitone given orally and daily for 2 weeks to infant rats
at 60 mg.kg- 1 and 15 mg.kg- 1 produces a 12 and 3% respective
reduction in brain growth (Booth,1988).
In addition, phenobarbitone fed to rats in a diet at 0.25%
results in a reduced gain in body weight. It is suggested that
the lower weight gain in animals chronically exposed to phenobar-
bitone occurs from alterations in hepatic metabolism, however,
the effect of phenobarbitone on food intake may also be a factor
in growth reduction (Booth,1988).
Mattson and Cramer(1989) report a decreased foetal head growth
associated with maternal use of phenobarbitone and this may be of
concern because phenobarbitone is currently the drug of choice 1n
pregnancy and treatment of neonates.
1.4.3 Systemic Toxicity
Haematological
Phenobarbitone 1S particularly benign 1n its likelihood to
produce serious haematological changes. There are no apparent
reports 1n the literature to indicate that blood tests ln an-
ticipation of haematological changes should be taken. Mild and
clinically unimportant leukopenia (3000-5000 white blood count)
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may occur following initiation of treatment, as is also observed
with the use of other antiepileptic drugs (Mattson and
Cramer,1989).
Megaloblastic Anaemia
Megaloblastic anaemia has been described during treatment with
phenobarbitone alone, or more commonly, when used with other an-
tiepileptic drugs (Rimmer and Richens,1988; Mattson and
Cramer,1989). Anticonvulsant megaloblastic anaemia occurs in less
than 1% of patients (Mattson and Cramer,1989). The aetiology and
pathogenesis of macrocytosis and megaloblastic anaemia during an-
tiepileptic therapy are unknown, but these conditions usually
respond to folate therapy.
Folate Deficiency
Frank serum and red blood cell folate deficiency is relatively
common. In a study done by Reynolds(1974) and referred to by Mat-
tson and Cramer(1989), a survey indicated a 27% to 91% subnormal
serum folate level in 52% of patients receiving long-term therapy
with phenytoin, phenobarbitone, or primidone.
Reynolds also reports an improvement in psychiatric abnormalities
in patients with low serum folate concentrations that were
treated with folate therapy. This was, however, a subjective ob-
servation and as such difficult to assess. No controlled trials
have been done to confirm this.
Mattson and Cramer(1989), however, discount the significance of
folate deficiency as being speculative. These authors state that
serum phenobarbitone concentrations decreased when folic acid was
given in very ~igh doses and, therefore, it is possible that
reports of seizure exacerbation resulted 1n part from ~he
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decrease ln drug concentration rather than from an epileptogenic
activity of folate; although the mechanism of this interaction is
unknown. These authors also make mention that animal studies done
by Klipstein (1964) showed that even in severe folate depriva-
tion, the brain maintains sufficient folate.
Vitamin K
Phenobarbitone and phenytoin can enter the liver of the foetus
and compete with vitamin K to prevent production of vitamin K-
dependent clotting factors. This can occur even ln the presence
of normal clotting factors in mothers receiving drug therapy. The
neonate can suffer from intraperitoneal, interthoracic, or
intracranial bleeding if vitamin K-dependent coagulation factors
are deficient. Vitamin K administered to mothers prepartum will
prevent this coagulation deficiency (Mattson and Cramer,1989;
Rimmer and Richens,1988).
Bone Disorders
Antiepileptic drug therapy may affect calcium and vitamin D meta-
bolism, leading to hypocalcaemia or, rarely, osteomalacia (Rimmer
and Richens,1988; Mattson and Cramer,1989). Induction of liver
enzymes leading to increased hydroxylation of vitamin D is a
probable mechanism for altered calcium metabolism (Mattson and
Cramer,1989).
1.4.4 Hepatic Disorders
Phenobarbitone is only a hepatotoxin in unusually susceptible in-
dividuals. Liver disease induced by the drug would appear not to
be dose-dependent and has a low incidence (Rimmer and
Richens,1988). The induction of hepatic microsomal enzymes has
been discussed before~ and this can lead to the enhanced metabo-
lism of other drugs or endogenous substances. These interactions




Phenobarbitone causes various types of skin reactions. These are
usually mild maculopapular, morbilliform, or scarlatiniform
rashes that fade rapidly when drug administration is stopped. The
incidence is reported to be as low as 1% to 3% of all patients
receiving barbiturates (Mattson and Cramer,1989).
1.4.6 Teratogenicity
There is an increased risk of foetal malformation in the offspr-
ing of mothers receiving antiepileptic therapy, but the role
played by the various antiepileptic drugs in their aetiology 1S
far from clear. Evidence for the teratogenic potential of
phenobarbitone is much less than for phenytoin (Rimmer and
Richens,1988; Mattson and Cramer,1989; Gallagher and Freer,1985).
1.5 DRUG INTERACTIONS
Most of the reported drug interactions involving phenobarbitone
occur in situations where phenobarbitone has altered the kinetics
of other drugs. Alteration in protein binding has not been impli-
cated as an important factor in any reported interactions.
However, phenobarbitone is a potent inducer of hepatic mixed
function oxidase enzymes and thus can alter the metabolism of
numerous drugs, e.g. warfarin, oral contraceptive steroids, and
various endogenous substances (Rimmer and Richens,1988;
Kutt,1989). The effect of enzyme induction on other drugs is
largely unpredictable and seems to be dependent on genetic fac-
tors and previous contact with environmental inducing factors
(Kutt,1989).
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Inhibition of the metabolism of phenobarbitone by other drugs may
also occur. Accumulation of phenobarbitone caused by valproate is
clinically important since it occurs predictably in the majority
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Chapter Two
The principles of applied pharmacokinetics and analytical methods
of determination of serum levels of phenobarbitone
2.1 INTRODUCTION
Advances have been made in the management of epilepsy in man over
recent years. Increased knowledge of antiepileptic drug phar-
macokinetics has been invaluable and the use of serum drug con-
centration monitoring is very useful for selected antiepileptic
drugs. Because of our greater awareness of the hazards of mul-
tiple antiepileptic therapy, in particular the risks of chronic
drug toxicity and the dangers of drug interactions, monotherapy
has become the general policy. The widespread availability of
reliable anticonvulsant drug assays have improved the prospects
for seizure control with monotherapy. Therapeutic drug monitoring
is a neglected field in veterinary medicine. The use of drug con-
centrations, pharmacokinetic principles and pharmacodynamic
criteria should be used to optimize drug therapy in refractory
animal cases.
2.1.1 Why monitor phenobarbitone levels?
The value of therapeutic drug monitoring is to maximize efficacy
of therapy and minimize side effects. It is well recognized in
human therapy that dosage of most drugs must be individualized to
achieve optimum efficacy with minimal side effects (Frewin,1982).
The therapeutic ranges of serum concentrations of antiepileptic
drugs have been reasonably well defined. The term "therapeutic
range" describes the relationship between the desired phar-
macologic activity and the drug concentration in serum or plasma.
Patients vary in their response to antiepileptics. Some benefit
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with concentrations that are low, whereas, others may require
high levels. Similarly, some patients, exquisitely sensitive to
the adverse effects of antiepileptic drugs, cannot tolerate even
low serum concentrations, while others can tolerate high con-
centrations without experiencing drug toxicity. Therefore, the
therapeutic ranges for the antiepileptic drugs are useful
primarily as guidelines in initiation of therapy (Welty et
al,1983; Kutt and Penry,1974).
In a study done on dogs where the serum concentrations, drug
dosages, and seizure control were monitored in 142 dogs receiving
a variety of antiepileptic treatment regimens, the author found
that of the dogs in which seizures were uncontrolled, a large
proportion had serum phenobarbitone concentrations that appeared
to be inadequate in spite of what was considered adequate dosage.
Further, for dogs given phenobarbitone, there was a sixfold
variation between dosage and an achieved serum concentration
(Farnbac~,1984). This underscores the need for serum concentra-
tion monitoring as an adjunct to any drug protocol in seizure
control since effectiveness is correlated far better with serum
concentrations than with oral dosing.
2.2 ANALYTICAL METHODS
During the past 25 years enormous advances have been made in the
development of sensitive and specific methods of determination of
drug and drug metabolite concentrations in biologic fluids. The
improved methodologies have resulted in an almost explosive
proliferation of commercial drug assay kits and instrumentation.
The different methods available differ in important aspects in-
cluding sensitivity, specificity, sample size needed, technical
difficulty, amount of technician time required and initial equip-
ment costs (Hendeles and Weinberger,1981). The following discus-
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sion traces the evolution of the available phenobarbitone assay
techniques from initial tedious, technically difficult assays to
modern day automated immunoassays with extremely rapid turnaround
time.
2.2.1 UV spectrophotometric assay
Phenobarbitone was initially measured by spectrophotometry. In
this method phenobarbitone is separated from other drugs, espe-
cially phenytoin, and extracted from the serum with organic sol-
vent and the absorbance of ultraviolet light is measured in a
spectrophotometer. Since most laboratories have a
spectrophotometer, the method does not require an investment in
new and expensive equipment. However, it does require a rela-
tively large sample size. In addition, a variety of commonly used
drugs (e.g. furosemide and aspirin) interfere with this assay,
producing false results. Patients are often treated with various
drugs, and these are not always reported to the laboratory. Ac-
cordingly, there is a great risk of false results, as has been
shown in quality control schemes (Johannessen,1989; Hendeles and
Weinberger,1981). Dogs, however, are not commonly treated with
concomitant medication and, therefore, this problem may not be as
acute as in the case of man.
other disadvantages include the need for more technician time and
the poor reproducibility of the results compared to other avail-
able methods. Even if spectrophotometric methods for determina-
tion of phenobarbitone can produce excellent results in the ab-
sence of interfering compounds, these techniques can hardly be




To avoid interfering substances and problems with
spectrophotometric analysis of phenobarbitone, thin-layer
'chromatographic systems have been useful. This technique also al-
lows analysis of multiple antiepileptic drugs. Instead of exten-
sive solvent partition extractions, separation was achieved on
the chromatographic plate. Although many of the thin-layer
chromatographic methods are specific and reproducible, they are
rather complicated, time consuming, with low output, and cannot
be recommended today (Johannessen,1989).
2.2.3 Gas-liquid chromatography
The determination of phenobarbitone by gas-liquid chromatography
(GLC) soon followed thin-layer chromatography and has been widely
used because of its high selectivity and sensitivity. The gas
chromatographic determination of phenobarbitone depends on
various conditions; variables include, specific quantification of
phenobarbitone alone or in multiple drug analysis, simple or" com-
plex extraction procedures, choice of internal standards, use of
derivatization, type of column, isothermal or programmed tempera-
ture, and type of detector.
The first step in a GLC assay involves an extraction step to dis-
solve the drug into an organic solvent. The sample plus an inter-
nal standard with chemical properties similar to the drug being
assayed, is then injected into the gas chromatograph. This is
carried into a high temperature column by an inert gas (e.g.
helium) which constitutes the mobile phase. Column temperatures
of looaC to 350°C volatilize the sample, which then comes into
contact with an inert stationary phase, usually coated with a
non-volatile liquid. As the mobile phase passes through the
column, the analyte is separated from other sample constituents
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based on affinity for the stationary phase. The mobile phase then
passes from the column to a detecting device that records peaks
graphically which correspond to the concentrations of the unknown
substances. The internal standard produces a reference peak.
Detecting devices include electron capture, mass spectrometry, or
more commonly, flame ionization (Bottorff and Stewart,1986).
Advantages of GLC include flexibility in drug assays (by altering
column length and temperature), simultaneous assay of parent drug
and metabolites and the ability to use small sample volumes. The
disadvantages are the time consuming procedure, high equipment
cost, column deterioration and the need for a skilled analyst.
Few laboratories currently use this technique (Hendeles and Wein-
berger,1981; Bottorff and Stewart,1986; Johannessen,1989).
2.2.4 High-pressure liquid chromatography
Determination of phenobarbitone by liquid chromatography (LC) is
a suitable alternative to GLC. Liquid chromatography is similar
to GLC except that the mobile phase is a liquid, usually a mix-
ture of acetonitrile or methanol with water. Compared to GLC, the
need for high temperatures is eliminated and columns packed with
stationary phase are kept at ambient temperature. Substances are
separated in LC according to their solubility in aqueous or or-
ganic solvents. Highly polar compounds will be more soluble in
highly polar solvents like water, whereas, less polar drugs will
dissolve better in organic solvents such as chloroform. As the
mobile liquid phase and the stationary phase come into contact in
a column, separation occurs in a fashion similar to other
chromatographic methods.
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The addition of 200 to 1000 pounds of pressure per square inch to
the separation column converts liquid chromatography into high
pressure liquid chromatography (HPLC), producing rapid separation
and determination of drug concentration.
Reverse phase liquid chromatography uses a non-polar column pack-
ing and polar mobile phase. This technique allows for the rapid
determination of phenobarbitone concentrations without the need
for an organic extraction step (Bottorff and Stewart,1986). The
reverse phase model is the one most often used, and offers dis-
tinct advantages over other LC methods (Johannessen,1989).
Liquid chromatography offers several advantages over gas
chromatographic methods, such as the absence of derivatization,
faster separation, better sample stability, smaller sample size,
and low cost once the method has been established.
The disadvantages are the high initial cost of the equipment; the
high degree of technician skill required and the difficulty in
performing stat or small batch testing due to the equipment
preparation time required. Large doses of some drugs e.g. am-
picillin, cephalothin, acetazolamide and trisulfapyrimidine cause
falsely elevated results under some operating conditions and rep-
resents another disadvantage of this technique (Hendeles and
Weinberger,1981; Bottorff and Stewart,1986, Johannessen,1989).
2.2.5 Gas chromatography-mass spectrometry
The quantitation of both phenobarbitone and its metabolites using
selected ion detection with a gas chromatograph-mass
spectrometer-computer system operated in the chemical ionization
mode has been reported in several studies. Alternatively,
phenobarbitone can be quantitated using a stable isotope-labelled
internal standard and chemical ionization/mass spectrometry
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without prior chromatographic separation. Selected ion monitoring
is the most sensitive and specific method for drug analysis. Al-
though this method can be considered a reference procedure, the
instrumentation is
It is the'refore
costly and technically difficult to operate.
limited to research laboratories
(Johannessen,1989).
2.2.6 Radioimmunoassay
The principle of a radioimmunoassay consists of a radiolabelled
ligand (usually 57CO, 3H, or 1251) that binds to a specific an-
tibody. Added unlabelled ligand competes with the label for bind-
ing sites. Measurement of the free or bound label is used for the
quantitation of drug present. Specific radioimmunoassays for
determination of phenobarbitone are not commercially available,
but the technique has been described in several reports.
Generally, radioimmunoassays have the advantage of excellent sen-
sitivity, and it is possible to make the antisera highly
specific. Furthermore, a large number of samples can be processed
and because of the ability to detect concentrations in the
picogram range, small sample volumes are adequate. The disadvan-
tages are the long turnaround times; the many interfering
substances; radiation hazards; inconvenience of recording and
disposing of radioactive waste; short shelf life of RIA reagents
and the need for daily calibration of the instruments. This
method 1S now less popular because of these many disadvantages
(Johannessen,1989; Hendeles and Weinberger,1981; Bottorff and
stewart, 1986) •
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2.2.7 Homogenous enzyme immunoassay
The development of the homogenous enzyme immunoassay (EMITR , Syva
Company) for phenobarbitone and other antiepileptic drugs has
been a major advance in the rapid and accurate analysis of
microsamples.
Whereas the label in radioimmunoassays is a radioactive isotope,
the homogenous enzyme immunoassays employ an enzyme as a label.
The assay is based on competition between drug in sample and drug
labeled with the enzyme glucose-6-phosphate dehydrogenase for an-
tibody binding sites. Enzyme activity decreases upon binding to
the antibody, so the drug concentration ln the sample can be
measured spectrophotometrically in terms of enzyme activity based
upon the conversion of oxidized nicotinamide-adenine dinucleotide
(NAD+) to the reduced form of NAD(NADH). No separation step is
required in this assay.
The phenobarbitone assay is easily run on one of the Syva Lab
Systems, including the Syva Advance Fluorescence Immunoassay Sys-
tem. In running phenobarbitone EMIT assay on the Advance System,
rather than measuring the absorbance of NADH in the turnover of
NAD+ to NADH, the fluorescence emission of NADH is measured
(Johannessen,1989).
The advantages of this method include the rapid turnaround time
and high precision. The disadvantages are the need to frequently
recalibrate the instrument and the technician time required to
perform dilution steps to analyse abnormally high serum con-
centrations (Bottorff and Stewart,1986).This technique is one of
the more popular methods currently available.
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2.2.8 Fluorescence polarization immunoassay
Another system of therapeutic monitoring of phenobarbitone and
other drugs is based on fluorescence polarization immunoassay
(FPIA). An automated analyzer TDx was introduced for such
measurements (Abbott Diagnostics).
This method combines competitive protein binding with fluores-
cence polarization to give a direct measurement without the need
for a separation procedure. All competitive immunoassays for
measuring therapeutic drugs are based on competition between the
drug in the patient sample and a labeled drug, called the tracer.
In the TDx system, the label on the tracer drug is the fluores-
cent dye, fluorescein. The polarization of fluorescent light
emitted by fluorescein tracer increases as the tracer is bound to
antibody. Polarization is measured using a sophisticated optical
detection system. A calibration curve stored in the systems
memory is used to automatically determine the concentrations of
unknown patient samples. FPIA is a precise, sensitive measurement
technique for rapid analysis of phenobarbitone in small sample
volumes (Johannessen,1989).
The advantages are the high degree of automation; rapid tur-
naround times, good sensitivity (lower limit of detection is 0.5
pg.ml- 1 at the 95% confidence limit), good stability of reagents;
good stability of calibration curves and the ability to analyse
small or large batches of samples. A disadvantage is the presence
of background interference inherent in some serum samples. In or-
der to minimize this, blank readings are taken and background in-
terferences are subtracted (Hendeles et al,1989; Bottorff and
Stewart,1986).
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2.2.9 Substrate-labelled fluorescent immunoassay
This type of test for determination of phenobarbitone utilizes a
technique in which the drug in the specimen competes with a drug-
labeled fluorogenic substrate for binding sites on the antibody.
The drug is labeled with a derivative of the fluorogenic enzyme
substrate umbelliferyl-a-O-galactoside. This fluorogenic drug
reagent (FOR) is nonfluorescent under the conditions of the as-
say. However, hydrolysis catalyzed by a-galactosidase yields a
fluorescent product. When antibody to the drug reacts with FDR,
it is virtually inactive as a substrate for the a-galactosidase.
Competitive binding reactions are set up with a constant amount
of FOR, a limiting amount of antibody to the drug, and the clini-
cal sample containing the drug. The drug in the sample competes
with the FOR for antibody binding sites. FDR not bound to an-
tibody is hydrolyzed by a-galactosidase to produce the fluores-
cent product. Hence, the fluorescence produced is proportional to
the drug concentration in the sample. Each test requires only a
small volume of serum or plasma and can easily be run on Ames
Fluorescent Chemistry Systems (Johannessen,1989).
2.2.10 Nephelometric inhibition immunoassay
Phenobarbitone is also measured by a rate nephelometric inhibi-
tion immunoassay, which is a homogenous, competitive binding as-
say for quantitation of haptens. It utilizes a precipitation pro-
cedure that does not require the use of fluorescent, radioactive,
or enzymatic tracers. The drug in each patient sample competes
with a drug-protein conjugate for a fixed amount of antibody that
is injected into each test reaction. Since the rate of light
scattering results only from the reaction of the antibody with
the drug-protein conjugate (and not the reaction with the drug in
the patient sample), the nephelometric signal is inversely
proportional to the amount of drug present in the test sample.
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This system has been very convenient for the precise determina-
tion of phenobarbitone in patient samples (Beckman Im-
munochemistry Systems).
(Johannessen,1989)
2.2.11 Radial partition immunoassay
A radial partition immunoassay for phenobarbitone has also been
developed. This assay is an integral part of the Stratus Enzyme
Immunoassay System (American Dade) which is a rapid and sensitive
procedure for the automated determination of therapeutic
phenobarbitone levels in serum and plasma, based upon the com-
petitive immunoassay technique. The clinical sample is premixed
with alkaline phosphatase labelled phenobarbitone and spotted
onto glass fiber paper containing preirnmobilized anti-
phenobarbitone distributed throughout the paper at the analysis
site. The two antigens then compete for binding sites on the an-
tibody molecule and any unbound labeled drug is washed out of the
field of view of the fluorometric analyzer. A substrate for the
enzyme label is incorporated into the wash solution and the en-
zyme reaction is initiated simultaneously with the wash. The
reaction rate of the bound fraction is measured via front surface
fluorometry. These rates are inversely proportional to the
phenobarbitone concentration. This system has proven to be a





2.2.12.1 Dry-phase apoenzyme reactivation
immunoassay system (ARIS)
Ames Diagnostics have recently introduced the ARIS reagent strip
test for determination of phenobarbitone which is performed on
the Seralyzer reflectance photometer (Ames). In the assay, the
drug in the sample competes with a flavine adenine dinucleotide
(FAD)-drug conjugate for binding to a specific antibody. The un-
bound conjugate then activates apoglucose oxidase to reconstitute
glucose oxidase, whose activity is kinetically monitored by a
coupled chromogenic reaction.
This homogenous competitive colorimetric immunoassay is partially
suitable for emergency use, for testing small batches of samples,
and wherever prompt results are needed. The dry reagent strip
technology is very convenient since all reagents are contained in
a ready-to-use cellulose pad fixed to a plastic strip, the
colour developed on the pad is kinetically monitored by a reflec-




Syntex Medical Diagnostics recently developed a noninstrumented
quantitative method for therapeutic monitoring of phenobarbitone
and other antiepileptic drugs using a factory-calibrated unit
test format and a novel single-level approach to quality control.
This method is based on the principles of immunochromatography,
which provides a number of convenient protocol advantages without
sacrificing assay performance or quality assurance, mainly be-
cause quantification is dependent on enzyme migration rather than
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enzyme activity. Since migration height is almost solely a func-
tion of a highly stable, immobilized, dry antibody reagent, this
test is extremely insensitive to environmental factors. The
specificity of the assay should be comparable to that of other
since the principle involved viz. use of monoclonal antibodies is
the same (Hendeles et al,1986).
The AccuLevel test consists of three main components: a
chromatographic paper strip coated with monoclonal antibodies
against a specific drug, an enzyme reagent that contains horse-
radish peroxidase-labeled drug and the enzyme glucose oxidase,
and a developing reagent that contains glucose and 4-chloro-1-
naphthol. It requires only 12 ~l of whole blood from a finger
prick and results can be obtained within 15 min using a simple 2-
incubation -protocol which does not require sample dilution
(Johannessen,1989). The ability to use whole blood rather than
serum or plasma means that the time-consuming centrifugation step
is eliminated, and no electronic or other instrumentation is
required. This is a real advantage, and this new approach to
therapeutic drug monitoring represents a step forward toward im-
mediate laboratory information for better patient care.
2.3 BIOLOGIC FLUID PHENOBARBITONE CONCENTRATIONS
The penetration of phenobarbitone to well perfused tissue occurs
~airly rapidly. The distribution of phenobarbitone is sensitive
to variations in the pH of plasma because it has a pKa close to
the physiological plasma pH. Acidosis causes a shift of the drug
from plasma to tissues, and alkalosis results in an increased
phenobarbitone concentration ln the plasma (Rimmer and
Richens,1988) .
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The phenobarbitone concentration in the CSF of adults is 43% to
60% of plasma concentration and correlates well with the unbound
phenobarbitone concentration in serum. The CSF levels in infants
are similar, ranging from 48% to 83% of plasma levels. The
phenobarbitone concentration in the CSF provides a reliable index
of phenobarbitone concentration in the brain. Under nonequi-
librium dosing conditions, actions of phenobarbitone correlate
better with CSF levels than with either dose or the rate of drug
administration (Rust and Dodson,1989).
Phenobarbitone concentrations are higher in CSF than saliva, a
more acidic but similarly low-protein fluid. Both salivary and
sweat phenobarbitone concentrations vary with flow rate. Salivary
phenobarbitone concentrations are also sensitive to pH changes
and saliva-to-serum phenobarbitone ratios have a greater interin-
dividual than intraindividual variation. It is therefore unwise
to use saliva for serum drug level monitoring in the case of
phenobarbitone (Rust and Dodson,1989; Rimmer and Richens,1988).
Since tears have a more constant pH than saliva, some inves-
tigators have suggested that tears may be more reliable than
other nonsanguinous fluids for estimating phenobarbitone con-
centrations (Rust and Dodson,1989).
Phenobarbitone readily crosses the placenta and is excreted in
breast milk. Infants born to mothers have equivalent serum con-
centrations in the immediate postnatal period. Concentrations of
phenobarbitone in breast milk were 36 ± 20% and 41 ± 16% of
maternal serum concentration in two studies referred to by Rust
and Dodson.
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Due to the variability of results from nonsanguinous fluids,
there is a danger in possible dosage adjustment errors. The
ability of newer techniques to measure levels as little as 12 ~l
(i.e. sufficient from a finger or heel prick) would make the sam-
pling and analysis of blood the preferred method.
2.4 WHEN TO DRAW SAMPLES
Since drug administration is a dynamic process, the timing of
sample collection can be critical to its proper interpretation.
It is important that samples for serum phenobarbitone concentra-
tion monitoring be drawn at steady state since levels measured
before steady state may be misleading. Steady state usually oc-
curs after approximately 3-4 weeks of stable dosage in man
(Gal,1986; Rimmer and Richens,1988) and in a study done on dogs,
Ravis et al(1984J concluded that time to steady state would be
between 8 to 15.5 days. However, if computer facilities are
available to perform the relevant complex calculations, then
samples may be drawn prior to steady state. Blood samples should
not be drawn during the absorption phase in view of the many fac-
tors that affect absorption of phenobarbitone (Robinson and
Taylor,1986). The absorption phase in adult man is 1-6 hours
after oral dosing (Rimmer and Richens,1988; Rust and Dod-
son,1989), and in dogs, maximum concentrations in plasma were
reached in 4-8 hours (Frey and Loscher,1985). Since peak/trough
fluctuations of phenobarbitone in the dog are relatively small,
the time when the blood sample is taken is not crucial.
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2.5 PHENOBARBITONE DOSING METHODS AND THE APPLICATION OF PHAR-
MACOKINETIC CALCULATIONS IN THE INTERPRETATION OF SERUM CON-
CENTRATIONS
The pharmacokinetic properties of phenobarbitone given orally,
intravenously, or intramuscularly, allows prediction of plasma
levels that are therapeutically efficacious. Until the last
decade, the use of phenobarbitone for the treatment of epilepsy
in man was based on empiric information of clinical response
rather than plasma or brain tissue concentrations attained during
therapy (Painter,1989). The clinical response to phenobarbitone
is still, however, the method of assessment of drug efficacy in
the dog, and only recently has an attempt been made to inves-
tigate the practical application of therapeutic drug monitoring
in the treatment of canine epilepsy (Morton and Honhold,1988).
Clinical pharmacokinetics concerns the use of pharmacokinetic
concepts and techniques with or without drug levels to promote
effective and safe therapy in patients and is based upon the con-
cepts of drug disposition. The interpretation of serum drug con-
centrations requires an understanding of the basic concepts of
pharmacokinetics and a background in pathophysiology and phar-
macotherapeutics (Beane,1979). However, in the case of phenobar-
bit~ne, this is is not that significant due to the drugs low
degree of protein-binding and its relative safety in respect of
drug interactions. Numerous dosing methods have been developed in
an attempt to improve the relationship between dose, serum
phenobarbitone concentration and response. The various phar-
macokinetic parameters that will affect the therapeutic objective
may be considered under the following headings:
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* Bioavailability
* Desired plasma concentration
* Volume of distribution and loading dose
* Clearance and steady-state
* Elimination rate constant (kd) and half-life
2.5.1 Bioavailability
Bioavailability has been defined as the rate and extent to which
the drug reaches the general circulation in an unchanged form. It
is defined in reference to direct intravenous administration
where the extent of drug entry is considered to be 100% and the
rate of entry is determined by the infusion rate. Bioavailability
of a particular dosage form is expressed as the fraction of the
administered dose that reaches the systemic circulation of the
patient and is designated by the parameter i, which varies be-
tween 0 and 1; i = 1 refers to 100% extent of bioavailability.
Although the rate of absorption can be important when a rapid on-
set of drug action is required, it is not usually important when
a drug is administered chronically.
The bioavailability of phenobarbitone varles among the different
formulations of the drug. Salts of phenobarbitone are more
soluble than phenobarbitone crystal. Preparations for intravenous
or intramuscular administration are from the sodium salt in
slightly alkaline solutions. Tablets for oral administration are
usually compounded from fine, somewhat polymorphic crystals of
the sodium phenobarbitone salt (Rust and Dodson,1989).
Phenobarbitone has a high bioavailability in adults after oral or
intramuscular administration. Studies in dogs and humans, at






phenobarbitone. In one study, the
phenobarbitone tablets was 95% and for
was 100% (Rust and Dodson,1989; Levy et
al,1987) .
To calculate the amount of drug which should reach the systemic
circulation, the administered dose is multiplied by the
bioavailability factor (I).
1 x DOSE = AMOUNT OF DRUG ABSORBED . •..•........•.. (1 )
The chemical form in which the drug is administered must also be
considered. When a salt or ester of a drug is administered, the
bioavailability factor (I) should be multiplied by the fraction
of the total molecular weight which the active drug represents
(S). The salt factor is not significant in the case of phenobar-
bitone where one is working from one dose to another of the same
form.
Drugs given chronically, as ln the case of phenobarbitone, are
usually administered at a constant rate. This then enables- one to
calculate the administration rate (Ri) which is the average rate
at which the absorbed drug reaches the systemic circulation. This
is calculated by dividing the amount of drug absorbed by the time
over which the drug was administered, or the dosing interval (~).
Ri = (S) (I) ( DOSE) • • • • • • • • • . • • • • • ( 2 )
Poor patient compliance may be mistaken for decreased
bioavailability. A true decrease in bioavailability may result
from a poorly formulated dosage form that fails to disintergrate
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or dissolve in the gastrointestinal fluids, interactions between
other drugs in the gastrointestinal tract, metabolism of the drug
in the gastrointestinal tract, and first-pass hepatic metabolism.
2.5.2 Desired plasma concentration
A therapeutic objective or endpoint must be selected when design-
ing a therapeutic regime. The preferred endpoint would obviously
be the relief of the treated condition, but this is not always
feasible and therefore, the drug serum concentration may used as
an intermediate endpoint. study of drugs which show some
relationship between serum concentration and the effect has
served to establish "therapeutic ranges" which is defined by a
Minimum Effective Concentration (MEC) and a Maximum Safe Con-
centration (MSC). The therapeutic range of a drug represent
average values only. A beneficial response to a drug may occur
below the MEC in a particular patient, and likewise, a patient
may exhibit drug toxicity at levels below the average MSC or
tolerate levels higher than the average MSC. Drug efficacy and
drug toxicity can, therefore, only be determined in the in-
dividual patient from clinical assessment of the response to the
drug. Drug levels are used in conjunction with clinical observa-
tions in order to investigate the contribution of the drug to the
patient 1 s clinical state.
The therapeutic range of phenobarbitone has been reported as 10
to 40 ~g.ml-1 (42-170 ~mol.1-1) in man(Painter,1989; Rimmer and
Richens,1988; Morton and Honhold,1988>. In a study done by Feely
et al (1980) and referred to by Painter, it was found that the
dose necessary to achieve a plasma concentration of more than 10
~g/ml were 1.0 to 1.5 mg.kg-1 for adult patients and 1.5 to
3 mg.kg-1 for children. The therapeutic range has not been calcu-
lated for canines but is assumed to be the therapeutic range for
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man (Morton and Honhold,1988; Schwartz-Porsche et al,1984;
Shell,1984).In a study done by Farnbach (1984) where seizure con-
trol was monitored in dogs, the serum concentrations of phenobar-
bitone ~n the dogs with effective control ranged from
14.3 pg.ml- 1 to 43.1 pg.ml- 1 •
The status of the binding of drugs to plasma proteins is often of
importance in the choice of the desired steady-state concentra-
tion. The drug concentration in plasma (Cp) which is reported by
the laboratory represents drug .that is bound to plasma protein
plus drug that is unbound or free. Phenobarbitone binding to
plasma protein plays a minor role in distribution. Binding is
readily reversible and independent of drug concentration, ionic
dissociation, and serum calcium concentration within the
physiological range of pH. In a study by Rust and Dodson (1989),
it was concluded that since approximately 55% of phenobarbitone
in serum is unbound, changes in the extent of phenobarbitone
binding in serum will have little effect on the unbound phenobar-
bitone level. In dogs, 45% to 46% of phenobarbitone is bound to
canine serum proteins, which is slightly less than the 48.5-50%
determined in human serum(Frey and Loscher,1985).
2.5.3 Volume of distribution
The volume of distribution (Vd) is the size of the compartment
necessary to account for all the drug in the body if it were
present at the same concentration everywhere as in the sample
measured. The volume of distribution does not necessarily refer
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to any real volume but is simply a constant relating the amount
of drug in the body (Ab) and the plasma concentration. The equa-
tion for the volume of distribution is expressed as follows:
Vd = Ab
Cp
• • • • • • • • • • • • • • • • • ( 3 )
where Ab = (S) (f) (DOSE)
Estimates of the apparent volume of distribution for phenobar-
bitone vary, sometimes as much as fourfold (Rust and Dodson,1989).
This wide range of values is in part attributable to the dif-
ferent methods that have been employed; most recent investigators
have used a single compartment kinetic model (Ravis et al,1984;
Pedersoli,1987). In dogs, the relative volume of distribution of
phenobarbitone was calculated to be 0.68 ± 0.029 1.kg- 1 (Frey and
Loscher,1985). In another canine study by Ravis et al (1984), a
value of 0.7436 ± 0.0698 1.kg- 1 for Vd/f was obtained using non-
linear least squares regression. To avoid the assumption of com-
plete systemic absorption, the value of Vd was expressed as a
function of the extent of absorption (f). In adults and children,
the relative volume of distribution ranges from 0.36 to 0.67
1.kg-1 after intramuscular doses and from 0.42 to 0.73 l.kg- 1
after oral doses. A wider range (0.39 to 2.25 1.kg- 1 ) has been
reported for newborns than for older children or adults(Rust and
Dodson,1989). This is probably the consequence of their rela-
tively larger extracellular fluid volume.
Since the volume of distribution is the parameter which accounts
for all of the drug in the body, it can be used to estimate the
loading dose necessary to rapidly achieve a desired plasma con-
centration.
LOADING DOSE = Vd x Cp
(S) (f)
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•••••••••••••••••• ( 4 )
Using a loading dose is beneficial in the case of status epilep-
ticus or where the patient/owner is particularly anxious to
rapidly bring the seizures under control. It has been recommended
that in the treatment of canine seizures, a oral loading dose of
30 mg/9 kg body weight stat should be given followed by a main-
tenance dose of 15 mg/9 kg every 6-24 hours(Booth,1988). In
humans, in the treatment of status epilepticus, a loading dose is
given in the form of an intravenous infusion at a rate of 100
mg.min-1 until a dose of 10 mg.kg-1 is achieved. This is also
used in the treatment of neonatal seizures to promptly achieve
therapeutically effective but nontoxic concentrations. Loading
doses of the drug are given intravenously at 15 to 20 mg.kg-1 to
achieve a predictable plasma level based on the volume of dis-
tribution for neonates (0.81 ± 0.18 l.kg-1 ). Plasma levels of
phenobarbitone can then be maintained in the range of 20 ~g.ml-1
with doses of 3 to 4 mg.kg-1 per day following loading
(Painter,1989).
2.5.4 Clearance
The overall apparent loss of an active drug moiety from the sys-
tem may be simplified and summarized by the parameter drug
clearance (Cl). Drug clearance principles are similar to the
clearance concepts in renal physiology, in which creatinine
clearance is defined as the rate of elimination of the creatinine
in the urine relative to the plasma creatinine concentration.
Clearance of a drug is, therefore, the rate of elimination (Ro)
by all routes relative to the concentration of drug in any
biological fluid.
and, therefore




• • • • • • • • • • • • • • • • • • • ( 6 )
Clearance does not indicate how much drug is being removed but
rather the volume of blood or plasma which would be completely
cleared of drug if it were present.
2.5.5 Steady state
In most cases of prolonged treatment, as in the case of phenobar-
bitone, it is desirable to maintain steady state drug concentra-
tions within a known therapeutic range. To maintain this desired
drug concentration (steady state), the drug must be replaced at a
rate equal to its loss. At steady state, therefore, the rate of
drug administration (Ri) and the rate of drug elimination (Ro)
must be equal.
Ri = Ro
and since Ro = Cl x Cp (Equ. 5)
therefore, at steady state
Ri = Cl x Cp•• • •••••••••••••••••••• ( 7 )
where Cp.. = average steady state concentration
If the average steady state plasma concentration and rate of drug




• • • • • • • ••••••••••••••• ( 8 )
For intermittent dosing, as in the case of oral dosing,
Ri = (S) (f) ( DOSE)
t
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the average steady state plasma concentration can
clearance can be calculated using the modified
Cl = (S) (f) (DOSE)
t X Cp••
•••••••••••••••••••••••••• (10)
If serial serum. drug concentrations are measured and plotted
graphically, then the area under the curve (ADC) can be calcu-
lated by the linear trapezoidal rule. The AUC is a measure of ex-
tent of drug absorption if clearance is constant. The total body
clearance at steady state can be calculated in a model-
independent fashion by using the following equation:
Cl = f x DOSE/AUC (1.hr- 1 .kg- 1 )
Maintenance dose
........... ( 11 )
If an estimate for clearance is obtained from the literature or
calculated from a steady state concentration-dose pair, the
clearance formula (Equ. 10) can be rearranged to calculate the
rate of administration or maintenance dose that will produce a
desired average plasma concentration at steady state:
Maintenance dose = Cl x Cp·· x t
S x f
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................... ( 12 )
2.5.6 Elimination rate constant (KE ) and half-life
The amount of drug removed per unit time (Ro) varies propor-
tionately with the drug concentration although the fraction of
the total amount of drug present in the body (Ab) which is
removed at any instant in time remains constant and independent
of dose. The follow equation describes the relationship between
Ro and Ab.
Ro = K E x Ab ......................... ( 13 )
Where K E is the elimination rate constant. This constant (K E ) is
the fraction of the total amount of drug in the body removed per





• • • • • • • • • • • • • • • • •••••••• I_I ••••• (14)
The elimination rate constant is often expressed,in its recipro-
cal form, as the half-life (t!s), which is defined as the time
required for the total amount of drug in the body or the plasma
drug concentration to decrease by one half. It can be calculated
from the following equation:
tts = 0.693 Vd
Cl
and thus, from equation (14)
· · · · · · · · · · · · · · · · · · · · · ( 15 )
tis = 0.693
· · · · · · · · · · · · · · · · · · · · · · · · · · ( 16 )
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The above equations combined with the knowledge of good estimates
of the population pharmacokinetic parameters of a particular drug
will ensure effective and safe dosing.
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Chapter Three
The pharmacokinetics of phenobarbitone in a group of healthy dogs
and the effect of food on the absorption of the drug
3.1 INTRODUCTION
Seizure disorders are amongst the most frequently seen neurologic
problems in small animal practice. Seizures often present a
diagnostic dilemma because they are episodic, frequently not
observed by the veterinarian and often present with no other
clinical abnormality. Epileptic seizures in dogs may be
controlled by a variety of drugs, the most common of which being
the administration of oral phenobarbitone alone or in combination
with other anticonvulsant drugs (Shell,1984).
The control of epileptic seizures is not as well described as is
the case in man. The dose of phenobarbitone in dogs as quoted in
the literature offers dose ranges as variable as 2 to 20 mg kg- 1
which may be divided into twice daily or even three times daily
dosing or given "to effect" (Oliver,1980; Shell,1984; Parker AJ,
1987 University of Illinois, Notes prepared for small animal
neurology seminar). As phenobarbitone in man requires only once
daily administration because of its long half life (50-120
hours), it would therefore appear that, in dogs, the clearance of
phenobarbitone is more rapid than in man thereby necessitating
more frequent dosing. Parker is of the opinion that the meta-
bolism of antiepileptic drugs in dogs may be up to ten times more
rapid the human rate. It is generally regarded by veterinarians
that only 60 to 70% of epileptic dogs are medically controllable
and in some breeds where epilepsy is considered to be hereditary,
this control may drop as low as 25% (Parker, 1987).
The purpose of the study was to determine the pharmacokinetics of
orally administered phenobarbitone to clinically healthy dogs
over 3 weeks on daily dosing. The effect of food on the absorp-
tion of the drug was also investigated.
-58-
3.2 MATERIALS AND METHODS
3.2.1 Model System
Ten clinically healthy adult dogs were selected (Table 1).
Ideally, for standardization, it was preferred that they should
have been of th~ same breed, mass and sex. In this study, it was
not possible to achieve this, and the dogs selected were of mixed
breeds and sex (eight males and two females). All were short
haired and without excess body fat, and of a tractable disposi-
tion.
The dogs were kenneled separately in standard kennels with out-
side runs. Adequate shade, warmth and shelter were provided.
Routine daily kennel management was applied ln accordance with
regulated practice. Diurnal changes in the environment were re-
corded by means of a maxlmin thermometer (see Table 2 in Appendix
A). The highest temperature recorded was 33 degrees Celsius and
the lowest 18 degrees Celsius.
Prior to the drug study, all the test animals were evaluated for
suitability and clinical soundness. This involved recording the
mass of each animal, a thorough physical examination, and the
collection of venous blood for haematological and biochemical
screenlng (full blood count, plasma(P)-glucose, serum(S)-urea,
serum(S)-creatinine, alanine transaminase(ALT), serum(S)-
bilirubin, serum alkaline phosphatase(ALP), total serum
proteins(S-TSP), serum(S)-albumin and serum(S)-globulins). On
conclusion of the drug trial, these same blood parameters were
again measured to determine the clinical soundness of the animals
and the adverse effect,if any, of the drug on any organ system.
Animals showing any deviation from the accepted norm were ex-
clude~ from the test group (see Table 3 & 4 in Appendix A). The
selected animals were inoculated (Rabguard TC, SmithKline Beecham
A.H. and Vanguard SIL, SmithKline A.H.) and dewormed (Vitaminthe,
Kruger-Med) ln accordance with standard veterinary preventative
medicine and quarantined individually in kennels for a period of
two weeks prior to the study. For the duration of the drug trial
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TABLE 1: CHARACTERISTICS OF THE DOGS (n=10) USED IN THE PHENOBARBITONE
PHARMACOKINETIC STUDY
N~.
I BREED I SEX I AGE I MASS I CONDITIONI I I , I
(yrs) , (kg)I
1 Lab. X G.S.D. M 4 24 lean
2 Mixed M 9 17 lean
3 Mixed M 1 15 lean
4 Fox Terrier X M 2 24 lean
5 Bull Terrier M 2 23 well muscled
6 Mastiff X M 7 23 lean
7 Bull Mastiff X M 8 28 lean
8 Lab. X Bull Terrier F 1 19 well muscled
I 9 G.S.D. F 2 22 lean(J)
0 10 Doberman M 8 27 lean
I
M = Male; F = Female; X = Mixed breed.
G.S.D. = German Shepherd Dog
Lab. = Labrador
the animals were provided with water ad lib. and
commercial pelleted dog food at 15hOO daily.
quarantine period, the dogs were again clinically






Sodium phenobarbitone (PHB) was administered orally in tablet
form (Lethyl, Lennon Lab., 30 mg per tablet) at a dosage rate of
5 mg.kg- 1 of body mass per day given as a single dose. Where
necessary, the tablets were scored and broken to provide as
accurate a dose as possible. It was administered with 20 mls of
tap water to all dogs on an empty stomach at OahOO each day until
the last day of the trial. In the case of Dog 7, however, the
above method of administration could not be achieved due to
aggression, but the dog readily swallowed the tablets in no more
than a teaspoonful of minced meat.
On Day 24 the normal daily food intake was given directly after
dosing in order to evaluate the effects of food on drug absorp-
tion.
Blood collection and sampling intervals
On the sampling days where multiple blood samples were required,
to facilitate the collection of blood, and to reduce the discom-
fort and stress and possible infection from multiple needle punc-
tures, an intravenous catheter (Bard I-Cath, 17g) was inserted in
the jugular vein of each test animal. Prior to insertion of the
catheter, the skin was aseptically prepared and a small bleb of
local anaesthetic (Procaine) was injected subcutaneously to
reduce the discomfort on insertion of the catheter. A small
amount of topical antiseptic ointment (Providine-iodine) was
applied to the skin surrounding the catheter. The catheter was
secured by means of a nonelastic bandage and covered with
adhesive plaster. Once the catheter was in position, blood could
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then be comfortably and easily withdrawn into a sterile dry 3 ml
syringe and deposited immediately into a capped test tube without
anticoagulant (Venoject-plain). The blood was then stored under
refrigeration (± 4°C) until centrifugation approximately 6 to 8
hours later. After a blood sample had been withdrawn, the
catheter was flushed with heparinized physiological saline in or-
der to prevent blood from clotting in the catheter between sam-
pling. The catheter was then plugged with the cap provided. This
technique of blood collection was used on Day 1 (the first day of
drug dosing), Day 22 (empty stomach) and Day 24 (with food), when
serial venous blood samples (n=9) were withdrawn over a 24 hour
period following drug administration (i.e. at 0.0; 0.5; 1.0; 2.0;
4.0; 6.0; 8.0; 12.0; and 24.0 hours after dosing).
On Day 7, 14, and 21, one blood sample was withdrawn from the
cephalic vein just prior to dosing (i.e. trough-level).
The volume of blood collected at anyone time did not exceed 3
mls. The collected blood was allowed to clot for approximately
one hour, and then centrifuged at 2500 r.p.m. for 5 min. at 20
degrees Celsius. On separation, the serum was aspirated by means
of disposable plastic pipettes and placed into pre-Iabelled con-
tainers (see Table 5 in Appendix A) and stored at -20°C until
assayed for PHB concentration.
3.2.3 Clinical observations and side effects
The animals were monitored daily for poor health or side effects
and in particular polyphagia, polydipsia, polyuria, sedation,
ataxia, and hyperkinesis which have been reported in the
literature(Oliver,1980; Shell,1984). These were recorded on a
data collection form ( see Figs. 2 and 2A-2J in Appendix A). The
animals mass was recorded weekly for signs of weight gain or
loss.
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3.2.4 Drug serum concentration assay
The concentration of phenobarbitone in the serum samples was
determined using the TDx System which uses the fluorescence
polarization immunoassay (FPIA) technology and ~s described in
Chapter Two (2.2.8).
3.2.5 Pharmacokinetic calculations
The serum concentration time pairs for each dog were fitted for
single dose, steady state without food, and steady state with
food using nonlinear least squares regression (STATIS 2, Version
2.1., 1987). A one and two compartment open model were compared
for goodness of fit by the residual sum of squares and the
Akaike's Information Criterion (AIC) (Yamaoka and Nagagawa,1978).
Estimation of the absorption rate constant (KA ) and elimination
rate ~onstant (K E ) could then be obtained.
The first-order elimination constant (K E ) was used to calculate
the biological half-life using equation (16):
tt = 0.693/K E •••••••••••••••••••••••••• (16)
The area under the curve (AUC) was calculated by the linear
trapezoidal rule. The total body clearance at steady state can be
calculated in a model independent fashion by using equation (11):
C I = f x DOSE I AUC (I. h r - 3. • kg - 3.) ••••••••• ( 11 )
Since phenobarbitone was not administered intravenously it is not
possible in this study to estimate the absolute bioavailability
(f) of oral phenobarbitone. Clearance in this situation is there-
fore more correctly termed oral clearance since it includes the
oral bioavailability factor (Cllf). In humans and dogs
bioavailability has been shown to be essentially complete (80
100%) (Rust and Dodson,1989; Levy et al,1986; Pedersoli et
al,1984). Oral clearance (Cllf) will therefore closely ap-
proximate total body clearance (Cl).
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3.2.6 Statistical evaluation
Analysis of variance was used in order to test variation between
subjects and also between treatments for half-life and the ADC
(P < 0.05 taken to be significant).
3.3 RESULTS
3.3.1 Drug absorption
The serum concentration time pairs for each dog were fitted for
single dose (Day 1), steady state without food (Day 22), and
steady state with food (Day 24), using nonlinear regression
(STATIS) (Figs. 3A-3J in Appendix B). A one compartment open
model was adequate to describe the data. Calculated phar-
macokinetic values indicating the absorption, accumulation and
excretion of PHB on Days 1, 22 and 24 are presented (Tables 6 & 7
and Fig.4). On the first day of dosing (Day 1), there was a
fairly rapid absorption of PHB with average peak serum concentra-
tions of 28.03 ± 2.84 pmol.1- 1 occurring two hours after dosing
(Fig.4 and Appendix B). Absorption rate constants (Tables 6 & 7)
showed a large variation (3.0085 ± 2.7085 hr- 1 and 0.9068 ±
0.7287 hr- 1 for Day 1 and Day 22 respectively).
Serum levels measured on Day 22 showed a trough concentration of
52.96 ± 8.40 pmol.1- 1 • Following drug administration, there was
again a fairly rapid absorption with an average peak concentra-
tion of 80.52 ± 6.63 pmol.1- 1 attained within 2 - 4 hours (Figs.
4 & 5 and Appendix B). Serum levels measured on Day 24 showed a
similar pharmacokinetic pattern as observed on Day 22, except
that the average peak concentration was slightly lower although
the trough level was similar (Figs. 4 & 5 and Appendix B).
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TABLE 7: PHENOBARBITONE PHARMACOKINETICS IN DOGS GIVEN ONCE DAILY ORAL DOSING
t.!. I KA. I KE
, AUC I Cl/F , ~ Cp2 I I I I I




DAY I DAY I DAY I DAY I DAY DAY I DAY DAY I DAY 22 I DAY 22I I I I I I I





MEAN I 46.3 I 29.3 I 3.0085: 0.9068: 0.0156 0.0242: 1656.17 1493.06: 0.0133 I 27.60I I I I
I I I I
I , , I
SD I 11.31: 4.6 I 2.7085: 0.7287: 0.0032 0.0036: 186.45 205.4: 0.0016 I 7.49I , I
I I I I I I
I I I I I ,
I CV % I 24.4 :. 15.7 I 90.02 I 80.35 I 20.5 14.9 I 11.3 I 13.8 I 12.0 I 27.18J"I , I I I I I I I
J1
I
~ Cp = average peak - trough serum concentrations
Fig. 4: Average serum phenobarbitone concentrations in dogs
for the initial day of dosing (Day 1), 22 days after












-- DAY 0 -+- DAY 22 (FASTING) 4--- DAY 24 (FOOD)
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Fig. 5: Average trough serum phenobarbitone concentrations
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3.3.2 Trough levels
\ Following Day 1 there was a slow accumulation in the PHB plasma
concentration followed by a decline to stable trough levels of
52.96 t 8.18 ~mol.1-1 which occurred approximately 22 days from
commencement of initial dosing (Fig.5 and Appendix B).
3.3.3 Half-life determination
The elimination half-life (tt) was calculated for each dog on
Day 1 and Day 22 from elimination constant (K E ) and using equa-
tion 16 (Chapter 2.6.5). The results are given in Table 7 & 8.
The mean elimination tt for Day 1 was 46.3 ± 11.3 hours and for
Day 22 was 29.3 ± 4.6 hours. Dog 5, a bull terrier, could not be
used in this comparison as there was doubt as to the dose he
received on Day 1. The results were compared by two-way analysis
of variance which showed that there was no significant difference
between subjects (P < 0.5), but there was a significant dif-
ference between Day 1 and Day 22 (P < 0.0066).
3.3.4 Area under the curve
AUC is a measure of the extent of drug absorption if clearance is
constant and is calculated by the linear trapezoidal rule. The
AUC values for the dogs were compared for Day 22 and Day 24 to
examine the effect of food on the extent of PHB absorption (Table
9). A difference of approximately 10% in the ADC was found when
Day 22 and Day 24 were compared (P = 0.0496), suggesting that
less drug had been absorbed when given with food (Table 7 & 9).
3.3.5 Clearance
The clearance was calculated from the AUC and using equation 11.
The mean clearance value for the sample group on Day 22 was
o•0133 ± O. 0016 I. h r -:1 •kg -1 (Tab1e 7).
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3.3.6 Clinical observations
The majority of dogs showed mild to moderate side effects to the
drug. The side effects of polyphagia, polydipsia and sedation
were initially observed from Day 2 in all test animals. In addi-
tion three dogs showed hindquarter ataxia. All these side ef-
fects, were, however, of short duration and were no longer evi-
dent by Day 10 (see Figs. 2A-2J in Appendix A).
3.3.7 Clinical pathology
No significant changes were recorded
biochemical analysis of the blood,
and compared remaining within normal
Table 3 & 4 in Appendix A).
in the haematological or
with all parameters measured
physiological limits (see
3.4 DISCUSSION
~henobarbitone distributes into most body tissues fairly rapidly
permitting the plasma pharmacokinetics to be described adequately
by a one compartment open model. Absorption rate constants showed
an 80 - 90 % variation but were within the ranges found in other
studies (Pedersoli et al,1987; Ravis et al,1984). The time
required to reach peak levels after oral PHB was between two to
four hours on Day 1, Day 22, and Day 24. It would therefore ap-
pear that the administration of food together with the tablets
has little effect on rate of absorption.
However, if one compares the extent of absorption using the ADC
values, there is a statistically significant difference between
administration with and without food. The lower ADC on Day 24 is
unlikely to be the result of further enzyme induction and In-
creased clearance as trough levels on Day 21, 22 and 24 are
similar. Thus, it would appear that food, together with the
tablets, reduces the extent of PHB absorption by approximately
10%. Continuous dosing together with food therefore, would be ex-
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pected to produce serum level profiles on average 10 % lower than
if dosing were given on an empty stomach. In general a difference
of less than 20 % is considered to be bioequivalent (United
states Food and Drug Administration,1977). Therefore it is un-
likely that feeding and simultaneously dosing the animals will
have a clinically significant effect on the control of epilepsy.
In this particular study the mean elimination half-life of PHB
declined from 46.3 ± 11.6 hours calculated for Day 1 to 29.3 ±
4.6 hours after three weeks of daily oral dosing. It is assumed
that this decline is due to microsomal enzyme induction (Ravis et
al.,1984; Saunders and Penry,1981). The initial rise in trough
levels from Days 1 to 7 and then the decline and stabilization by
3 weeks supports this assumption. Both the initial and final
half-lives in this study were considerably shorter than those
reported in a single dose study by Pedersoli et al.(1987) where
the tt for oral dosing was 72.3 ± 15.5 hours. The half-life of
53.0 ± 15 hours reported in another study (Ravis et al.,1984)
after 5 days of oral dosing is comparable to the initial half-
life reported in this study. Five days 1S probably not long
enough for enzyme induction to reach a maximum. Another possible
reason for the relatively short half-lives found in the present
study could be the relatively short sampling interval of only 24
hours after dosing whereby distribution may still be operative.
The other studies sampled over 288 and 131 hours respectively
(Pedersoli et al.,1987; Ravis et al.,1984). Considerable inter-
subject variation 1n the half-life has also been reported
(Pedersoli et al.,198?; Ravis et al.,1984) which was not as ap-
parent in this study (coefficient of variation for Day 22 = 15.7
%) possibly because of our larger numbers.
steady state is assumed to be close to five times the elimination
ti. Using this value to estimate the time necessary to reach
steady state in this study would have given a period of n1ne to
six days utilizing our calculated tt for Day 1 and Day 22 respec-
tively. Ravis et al.(1984) in their study assumed steady state
would be reached at approximately eleven days, However, in this
trough levels only stabilized between 14 - 21 days, as indicated
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in Fig.4. It is therefore apparent that approximately three weeks
of daily dosing is required before enzyme induction is complete
resulting in stable clearance and steady state levels.
Clearance of phenobarbitone in dogs was calculated as 0.0133 ±
0.0016 1.hr-1 .kg-1 which is more than four times that for humans
(0.0032 1.hr-1 .kg-1 ) (Gal, 1986). Using oral clearance, the fol-
lowing equation can be used to calculate a dose for a desired
concentration (C p ) in dogs. [Note 0.232 is the conversion factor
from ~mol to mg i.e. 1 ~mol = 0.232 mg phenobarbitone]
Dose = CII! x Cp x Dosing Interval x 0.232 •••.••••••.• (17)
Using the above equation, therefore, indicates that a dose of
5 mg.kg-1 .24 hrs-1 should maintain an average serum concentration
in the region of 65 ~mol.I-1 which is within the therapeutic
range determined in man (40 110 ~mol.I-1) (Saunders and
Penry,1981; Gal,1986; Shell,1984). Chapter four will examine the
practical application of predicting the serum concentration for a
desired therapeutic effect in dogs.
The relatively small fluctuation in peak and trough serum con-
centrations at steady state (5.44 ± 1.22 ~g.ml-1 as shown ln
Table 10) found in this study would support once daily dosing.




From the results of this study, it can be concluded that:-
1. An oral dose of 5 mg.kg- 1 should give average serum PHB
concentrations of 65 pmol.1- 1 in adult dogs.
2. Once daily dosing
small peak-trough
1.22).
may be adequate since relatively
fluctuations were observed (5.44 ±
3. The dose may be given with food although the extent of
absorption is approximately 10 % less than when given
on an empty stomach. This is probably of little clini-
cal significance especially if serum levels are
monitored.
4. Side effects of polyphagia, polydipsia, sedation and
ataxia are commonly observed in the first two to nine
days but disappear thereafter. This is probably due to
tolerance to the effects.
5. After initiation of therapy, dosing should continue un-
changed for three weeks (steady state) before measuring
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Chapter Four
The assessment of therapeutic drug monitoring as an aid in the
treatment 'of clinically diagnosed epileptic dogs.
4.1 INTRODUCTION
The therapeutic range of serum concentrations of phenobarbitone
has been reasonably well defined in man (Welty et al,1983;
Shell,1984; Painter,1989). The term "therapeutic range" describes
the relationship between the desired pharmacologic activity and
the drug concentration in the plasma or serum (Welty et al,1983).
Therapeutic ranges, determined from clinical trials, are not
rigidly defined but., rather, represent average values.
Patients vary in their response to antiepileptic drugs. Some
benefit with serum concentrations that are low, while others
require concentrations above the therapeutic range. Tolerance to
phenobarbitone may also develop, whereby the response is
diminished with time for a given concentration (Rowland and
Tozer,1989). There may also be differences in the absorption and
metabolism of the drug. Thus different patients may require
highly varying dosages of the same drug to achieve and maintain
serum concentrations in the therapeutic range. Use of standard
dosage regimens may, therefore, often result in unpredictable
serum concentrations and response (Welty et al,1983).
For man, a considerable body of information describing the vari-
able absorption and elimination pattern of phenobarbitone is
available (See Chapters 1 & 2). Due to to the variability of the
kinetics of the drug in the individual and the seizure pattern
irregularity, antiepileptic drug therapy should be tailored to
the individual patient (Welty et al,1983; Kutt and Kiffin
Penry,1974; Painter,1989).
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Monitoring the blood levels of antiepileptic drugs has increased
the efficiency and safety of drug therapy in epilepsy. It can
facilitate individualization of dosage regimen, reveal irregular
drug intake or non-compliance, and can identify the responsible
agent in intoxicated patients on multiple drug therapy (Kutt and
Kiffin Penry,1974). It has been noted, however, by some authors
that before the development of methods to determine anticonvul-
sant drug blood levels, many patients were managed successfully
on clinical grounds alone (Livingstone et al,1975).
Historically, much of the information upon which the veterinarian
has relied was derived from human medicine and the veterinary ap-
plication of a considerable portion of this is subject to serious
question. For example, Shell(1984) states that blood levels are
clinically effective 12 to 24 hours after oral administration.
However, in the preceding study on healthy dogs (Chapter 3), the
peak serum conc~ntration levels after 24 hrs were approximately
35% lower than that observed three weeks later at steady state.
It may be possible to achieve immediate effective control by
giving a large enough loading dose, but this tends to cause
pronouced sedation which is often as alarming to the client as
are the seizures. The same author also states that effective
blood levels in the dog are similar to that of man, with toxicity
developing with blood levels of phenobarbitone greater than 40
~g.ml-1 (Shel1,1984). However, clinical trials have provided con-
flicting evidence.
In a study on dogs given phenobarbitone by Farnbach (1984), a
sixfold variation was observed between dosage and achieved serum
concentration. In this study, 20 of 42 dogs having seizures and
receiving phenobarbitone were controlled at serum concentrations
ranging from 14.3 to 43.1 ~g.ml-1. This author concluded that
there was a need for serum concentration monitoring as an adjunct
to any drug protocol in seizure control since effectiveness was
correlated far better with serum concentrations than with oral
dosage.
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In a recent study describing a consultative service to veterinary
surgeons to treat epileptic dogs, it was concluded that, whilst
there was little confirmation of the diagnosis of idiopathic
epilepsy in most of the cases involved and no direct measurement
of hepatic function in 16 of the cases, their results
strengthened the case for the use of therapeutic drug monitoring
in canine epilepsy (Morton and Honhold,1988). Their results ob-
tained in the first two years of drug monitoring suggest that
this service can be valuable in the improved control of seizures.
The purpose of this study was to investigate the practical ap-
plication of therapeutic monitoring as an aid in the treatment of
canine epilepsy.
4.2 MATERIALS AND METHODS
4.2.1 Selection and treatment of patients
Patients were selected from epileptic dogs presented for treat-
ment at the Durban Veterinary Clinic over a 24 month period.
Other veterinary practices in the Durban and surrounding area
were invited to participate in this study and an appeal for un-
controlled epileptic dogs was placed in the local newspaper.
Despite frequent contact with the other practices, only one
patient from another practice was referred for serum monitoring,
and only one person responded to the newspaper appeal.
All presenting patients were given a thorough clinical examina-
tion which included screening for internal parasites, and the
determination of serum electrolyte and enzyme levels to evaluate
the presence of organ disease or failure which may be the
aetiological cause of the seizures. Two dogs were eliminated on
the basis of uremia due to renal failure, and one dog had
evidence of hepatic cirrhosis.
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Those dogs having seizures from no other discernible cause were
diagnosed as suffering from idiopathic epilepsy and, with the
permission of the client, were selected for serum monitoring.
Details of the patient's breed, age, mass, sex, seizure frequency
at the time of sample, current drug regime, t~me and method of
drug administration were recorded (see Fig. 6 in Appendix C). The
owners of these dogs were given an "Epileptic Diary" to record
the seizure frequency and interval, daily medication times, any
change in dose, and any other observation or comment. This diary
was used to evaluate the dogs progress and also appeared to in-
crease the owners enthusiasm in assisting in the project. Concur-
rent records were kept by the investigator, noting seizure
frequency, medication, any clinical evaluations for drug
toxicity, anecdotal comments from the owner, and reasons for any
change in medication. On return of the patients for blood collec-
tion to determine the drug serum concentration, the clients were
questioned as to the seizure frequency and further verification
was by phone.
Dogs diagnosed as suffering from idiopathic epilepsy, and who had
not received any previous medication, were placed on a phenobar-
bitone dosage rate of approximately 5 mg.kg- 1 body mass glven
once daily. This dosage level was shown to be able to, with
reasonable accuracy, achieve a drug serum concentration which was
in the therapeutic range for man (refer Chapter 3). It was
stressed to the owners to administer the daily dose at the same
time each day and to record whether it was given with or without
food. All observations were to be recorded in the diary. Owners
were cautioned as to the probability of the appearance of side
effects and the expected duration thereof. All patients were
requested to return in 3 weeks for evaluation of efficacy of
treatment and a blood sample was drawn to determine the serum
drug level at the current steady state in order to provide a base
line. This was useful in judging compliance or for estimating the
extent of a future change in dosage, if this became necessary.
Dogs who had recorded no further seizures on commencement of
therapy were maintained on the same dose. Those dogs where
seizures were still present, were placed on a higher dose based
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on the serum concentration of the drug
return after 3 weeks for re-evaluation.
mined after each change in dosage.
and agaln requested to
Blood levels were deter-
Dogs that were currently on phenobarbitone therapy for idiopathic
epilepsy and still uncontrolled were initially monitored to
assess the serum concentration of the drug and then the dosage
was increased. They too returned after 3 weeks in order to assess
efficacy of treatment and to determine the serum concentration.
A total of 14 dogs were evaluated comprising a variety of breeds,
mass, and of both sex (Table 11). From these dogs, 20 serum
samples were analyzed to determine the drug serum concentration.
The importance of compliance with the recommendations was
stressed and, on the basis of the results of the drug serum con-
centrations obtained, the drug regimens appear to have been com-
plied with in all cases.
4.2.2 Blood sampling
Blood samples were taken aseptically from the cephalic vein and
the serum separated by centrifugation. The serum was then stored
at -20°c until analyzed.
4.2.3 Drug assay
All serum samples were assayed by the Drug studies Unit of the
University of Durban Westville. Serum concentrations of phenobar-
bitone were determined by the use of fluorescence polarization





A common form of representing concentration-response is a plot of
the intensity of response against the logarithm of the drug con-
centration. In the treatment of epilepsy, a graded response with
concentration may occur but usually the response is all or noth-
ing. Logistic regression is used to assess the frequency of
patients reponding or not responding to a stimulus, which, in
this case is phenobarbitone serum concentration.
Each patients clinical state was categorized by the binary de-
pendent variable of "responsive" or "nonresponsive" on the basis
of seizure control. Phenobarbitone serum concentrations versus
response/non-response were analyzed by logistic regression to
determine the Cpso of phenobarbitone for the control of seizures.
The Cpso (analogous to ED so > is the phenobarbitone serum con-
centration at which there is a 50% probability of suppressing
seizures (Ausems et al.,1988) •.
Logistic regression is a method for analyzing proportions
analogous to multiple regression for continuous variables, where
proportion is the outcome variable which in this case is con-
trolled or not controlled. It allows both the inclusion of con-
tinuous explanatory variables and the assessment of interaction
between the variables(Kirkwood,). Logistic regression is so
called because it investigates the linear dependence of the
logistic transformation of the outcome variable on several ex-
planatory variables, where the logistic transformation, or logit
for short, is defined as:




The model is fitted using a mathematical technique called maximum
likelihood, which also takes account of the fact that the varia-
tion of a proportion has a binomial distribution. Both theoreti-
cal and empirical considerations suggest that when the dependent
variable is an indicator variable, the shape of the response
curve will frequently be curvilinear(Armitage and Berry,).
Predictive performance
Based on the pharmacokinetic values for phenobarbitone in normal
healthy dogs, the population value (n = 10) for drug clearance
was obtained (Chapter 3.3.5) and by rearranging Equation 12, a
steady state serum concentration could be predicted. This could
then be extrapolated to the group of epileptic patients. In order
to assess the accuracy of predicting the serum concentration in
this naive group, the proximity of the prediction to the true
(observed) value is the difference between the two. The quantity
that results from the prediction mlnus the true value is termed
the prediction error (pe)(Sheiner and Beal,1981; Miller and
Rheeders,1989). From this value, the bias (average predictive
error) and precision (root mean squared error) of the predictions
can be determined.
A two-tailed student's t test is used to assess whether the mean
prediction error was different from zero, indicating bias. The
Null Hypothesis, Ho, states that mpe = 0 i.e. the mean prediction
error does not significantly deviate from zero. Rejection of Ho
at the 95% confidence level using an unpaired t-test indicates
the presence of significant bias (Fotheringham,1982).
4.3 RESULTS
4.3.1 Therapeutic drug monitoring
The results of the serum concentrations attained and the clinical
state achieved is presented in Table 11. Of the 14 dogs examined,
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10 dogs were controlled after primary dosing, 1 dog was con-
trolled after adjusting the dose twice, and 3 dogs remained un-
controlled despite therapeutic drug monitoring and the consecu-
tive increase in dosage. The lowest drug serum concentration at
which control was achieved was 12.64 ~g.ml-1 and the highest
serum concentration where control was not achieved was 48.64
pg.ml-1 • There appeared to be a great individual variation in the
effective concentration.
4.3.2 Statistical analysis by logistic regression
The interaction of the binary dependent variables of responsive
and nonresponsive clinical states were analyzed by logistic
regression for concentration, breed of dog, age, and sex. The
following results were obtained:







A probability factor of P < 0.05 is taken to be statistically
significant. It can therefore, be seen that no significance was
observed between concentration and effect, breed and effect, sex
and effect, and age and effect. The dose divided by the mass was
also analyzed and P was found to be 0.2085 (P = 0.2085), which is
also not statistically significant.
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Population profiles of the variables dose and concentration were
examined which yielded probabilities of 0.2555 and 0.3001 respec-
tively and' are, therefore, also not statistically significant.
4.3.3 Predictive performance
In the assessment of predictive performance, the mean prediction
error was positively biased but this was not significantly dif-
ferent or deviant from zero (-5.0937 < 2.47 > 5.2577, 95% Cl).
The predicted concentration was within 5 ~g.ml-1 of the ob-
served concentration with 95% confidence (Table 13). This means
that on average the concentration predicted using population
pharmacokinetic parameters of phenobarbitone determined in
healthy mixed breed dogs was only slightly higher than the con-
centration measured in the epileptic dogs.
In the assessment of absolute precision using mse, the square
root of mse was 10 ~g.ml-1 indicating that, at 95% confidence
limits, the precision of prediction would be within 10 ~g.ml-1.
4.4 DISCUSSION
In a study done by Farnbach(1984), it was postulated that serum
concentrations should be maintained between 15 and 45 ~g.ml-1 to
achieve clinical efficacy in 50% to 70% of epileptic dogs. This
study tends to confirm this statement. The therapeutic range of
phenobarbitone, as shown in this study and in others, is fairly
wide with clinical control occurring at varying concentrations.
Some dogs were controlled at relatively low serum concentrations,
whilst other dogs were not controlled at high and seemingly toxic
levels (Table 11) (Morton and Honhold, 1988). Some authors
support the monitoring of serum drug concentrations as an essen-
tial aid in the treatment of idiopathic epilepsy on the basis
that there appeared to be a sixfold variation between dosage and
achieved serum concentration. This implied that effectiveness is
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correlated far better with serum concentrations than with oral
dosage (Morton and Honhold,1988; Cunningham et al,1983;
Farnbach,1984>. Our results, and in particular the results of the
predictive performance does not support the above variation
which is probably due to noncompliance. Although the sample size
in our study was small (n = 14), there would appear to be poor
relationship between effect and serum concentration and no EC so
could be calculated. However, the predictive performance indi-
cates that the prediction error is statistically unbiased and
that serum concentrations at steady state can be achieved within
5 pg.ml- 1 using population pharmacokinetics of clearance. This,
combined with clinical assessment of efficacy of treatment, would
appear to be a more practical approach to achieving control of
epilepsy in the dog.
Morton and Honhold (1988) also observed a large difference in the
dosage required to achieve therapeutic levels. In this study,
this large difference was not observed. However, it was noted
that where a high dosage was given in an attempt to achieve con-
trol, the predictive value was in most cases considerably dif-
ferent to the observed value (Table 11).
Drug serum monitoring does, however, have its place in the
assessment of side-effects, where seizures recur 1n patients
whose attacks were previously well controlled, and, also in the
determination of noncompliance (Kutt and Kiffin Penry,1974).
As was mentioned previously, although a relatively common ailment
of dogs, very few epileptic cases were forthcoming despite a wide
local appeal. Those cases that were forthcoming were often
epileptics that were not adequately controlled despite incremen-
tal doses of phenobarbitone administered in the first place.
There is, therefore, a certain degree of bias in the results ob-
tained and presented. The relatively small sample size (n = 20)
was insufficient to statistically differentiate between those
dogs that would have readily responded to therapy at average
doses, and those that would be non-responsive. It was determined
by a statistician (Professor Clark, University of Natal, personal
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communication,1990), that, in the order of 100 patients would be
required to provide results that would have sufficient power
(small probability of concluding no relationship when there in
fact is one).
4.5 CONCLUSIONS
Improper prescription by the veterinarian and the improper ad-
ministration of phenobarbitone by the owners, are the most common
causes of anticonvulsant failure. A true anticonvulsant failure
is failure to control seizures when the drug has been correctly
prescribed and correctly administered and the dose slowly in-
creased until toxic signs are seen. Tolerance to phenobarbitone
can occur and the dosage then needs to be increased. In this
case, a serum concentration would he of interest. Drug interac-
tions with concomitant drug therapy should also be examined where
tolerance is suspected.
This study does not, therefore, support that therapeutic drug
monitoring (TOM) should be done routinely in the treatment of
canine epilepsy. However, as discussed previously, more patients
would be required before this statement can be completely jus-
tified. Therapeutic control of epilepsy should, therefore, be
based on the frequency of seizures, the client concern for the
degree of control, and the time to onset of control. Predictive
serum concentrations can be made with reasonable confidence, with
follow-up examinations after 3 weeks. In the event of. uncon-
trolled seizures, TOM may be advantageous in the control of dogs
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TABLE 2: MINIMUM AND MAXIMUM ENVIR<N1ENTAL TEMPERATURES
RE<XlIDED OVER THE TRIAL PERIOO



























TABLE 3: HAEMATOLOGY VALUES FOR THE EXPERIMENTAL DOGS RECORDED
PRE - AND POST-TRIAL (POST TRIAL VALUE IN BOLD)
PARAMETER : UNITS 1 2 I 3 4 5 I 6 7 8 I 9 10I I I
I I I
I I
9 13.7 22.0 18.6 11.6 18.0 I 8.6 7.1 14.8 I 8.9 9.5I I
WBC : x 10.1-1 11.5 22.6 15.2 26.1 21.6 : 14.0 4.6 15.7 : 13.5 11.7
12 6.84 5.26 6.78 6.14 7.46 I 5.96 6.57 6.31 I 7.12 6.67, I
RBC : x 10.1-1 6.02 4.76 7.66 6.28 6.62 5.53 5.93 4.44 I 6.48 4.83I
I 16.9 10.6 " 15.5 13.0 18.1 12.8 13.8 15.2 I 17.1 15.1, I
Hgb : g.d1-1 15.1 10.1 17.3 13.6 16.0 12.6 13.6 11.6 : 16.7 11.6
I 0.480 0.386 0.452 0.384 0.517 0.383 0.398 I 0.431 I 0.483 I 0.429, I I
Hct : 1.1-1 0.413 I 0.327 0.50 0.383 0.458 0.350 0.372 I 0.316 0.451 0.314I
70.1 58.1 66.6 62.4 69.3 64.3 60.5 , 68.2 67.7 64.3,
MCV : f1 : 68.6 59.9 65.1 60.9 69.1 63.2 62.6 1 71.0 69.6 64.91
24.7 20.1 f 22.9 21.2 24.3 21.5 , 21.0 I 24.1" 24.0 22.7I
MCH : - : 25.0 21.1 I 22.6 21.6 24.2 22.7 22.9 I 26.1 25.7 24.1I I
35.2 34.6 I 34.4 34.0 35.0 33.4 34.7 I 35.3 35.4 35.3, I
MCHC : g.d1-1 : 36.5 35.3 I 34.7 35.4 35.0 35.9 36.6 36.7 36.9 37.0I
I
I : 13.1 17.3 I 13.9 16.7 13.1 15.9 20.8 13.8 14.1 10.9~ I I
0 RDW I % : 12.0 22.4 13.5 14.8 13.6 15.7 19.6 13.9 13.7 11.1I I
9 I 209.0 229.0 238.0 clumped clumped clumped 105.0 279.0 239.0 276.0I
PLT : x 10.1-1 : 181.0 231.0 289.0 72.0 69.0 177.0 "107.0 153.0 255.0 clumped
0.261 0.281 0.336 - - f - 0.125 0.337 0.333 0.279
PLT CRIT I : 0.249 0.288 0.388 0.089 0.090 0.256 0.161 0.250 I 0.393 6.112I I
12.5 12.2 14.1 7.7 13.9 - I 11.9 12.1 I 14.0 J () . 1I I
MPV : f1 : 13.8 12.5 13.4 14.9 14.3 14.4 : 15.0 16.3 , 15.4 15.0I
14.2 15.5 15.1 16.9 15.5 - I 15.0 14.6 , 15.0 J4.8I I
PDW I : 14.9 15.4 15.5 15.6 17.5 15.1 : 15.5 14.9 I 15.2 17.1I I
70.0 80 - 69.0 78.0 - I 82.0 81.0 I 78.0 71.0I I
LYMPH I % : 69.0 - 80.0 79.0 75.0 77.0 I - 82.0I I
9 : 10.0 17.5 - 7.9 ' 14.0 - I 5.8 12.0 I 6.9 I 6.8I I I I
LYMPH : x 10.1~: 7.9 - 25.1 20.5 16.4 10.8 I - 12.9I
47 53 53 45 69 48 I 63 59 I 46 I 56I I ,
NEUTROPHILS I % : 46 56 73 62 74 63 : 82 78 I 70 I 5fiI I I
27 26 26 23 14 34 I 18 26 I 25 I 23I I I
LYMPHOCYTES I % : 18 18 15 16 13 15 : 11 7 I 12 I 24I I I
7 I 12 6" 13 13 9 I 10 5 I 5 I ~I I I I
MONOCYTES I % I 9 : 10 8 4 3 13 I 6 3 I 6 I 14I 1 I I I
TABLE 4: SERUM BIOCHEMISTRY VALUES FOR THE EXPERIMENTAL DOGS
RECORDED PRE - AND POST-TRIAL (POST TRIAL VALUE IN BOLD)
PAfWvlETER : UNITS I 1 I 2 I 3 I 4 t 5 I 6 7 8 9 10I I I I I
I I I I
I I I I
5.5 : 7.2 : 3.2 4.1 I 5.6 4.2 5.2 5.9 3.7 5.3I
UREA : rmvl.l-:J..: 5.9 : 6.8 : 3.6 5.1 I 5.'2 3.3 4.5 5.7 5.4 5.1I
90 I 81 I 72 68 t 78 102 90 90 94 96I I I
CREATINE : urool.1-1 : 102 : 102 ' 104 89 99 90 79 95 104 71
4.0 4.1 4.2 4.4 4.5 4.0 3.9 3.7 I 3.8
GLUCOSE : rmv1.1-1 : 3.8 : 4.0 4.5 4.1 4.3 '4.5 3.8 4.5 3.9 4.3
99 I 86 78 107 30 61 55 72 67 38I I
ALl{ PHOS I i.u : 193 : 132 97 95 77 : 283 289 116 93 103I
1 I 1 1 I 1 1 I 1 1 I 1 5 2I I I
TOTAL BILl. : umo1.1-1 : 2 I 1 3 I 3 7 1 2 5 2 1I I
62 I 89 63 I 72 84 68 66 63 54 67I
T.S.P. , 9.1-1 I 72 I 86 68 65 86 67 67 65 64 63I I I
I
, I 24 I 27 32 26 28 26 I 24 29 28 26I I I
'-.0 ALBUMIN , g.l-:J.. I 24 27 31 26 I 28 21 22 26 27 20.......... , , ,
I I I 38 62 31 46 I 56 42 42 34 26 41I I I
GLOBULIN , ~.J ....~ I 48 59 37 39 , 58 45 45 39 37 43I I ,
3 4 2 1 I 2 0 2 2 2 3I
Garrrna.GT I i.u. t 4 10 4 4 I 4 3 2 3 3 3I , I
16 21 42 16 I 21 22 15 18 15 15I
AST , i.u. t 19 24 29 19 I 22 22 28 27 29 31I I ,
37 18 38 16 I 18 17 I 28 25 34 45I I I
ALT I i.u. t 63 15 33 16 I 20 63 I 46 18 48 I 50I I I I I
TABLE 5: CANINE PHENOBARBITONE DRUG





1/2 hour post. B
1 hour post. e
2 hours post. D
4 " " E
6 " " F
8 " " G
12 " " H






1/2 hour post. N
1 hour post. 0
2 hours post. P
4 " " Q
6 " " R
8 " " S
12 " " T





1/2 hour post. W
1 hour post. X
2 hours post. Y
4 " " Z
6 " " AA
8 " " BB
12 " " CC
24 " " DD
---000---
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TABLE 5A INDIVIDUAL PlIE.H)BARBITONE cnNCENrRATIONS (pg .1-1 ) FOR ALL THE rx:x;s OVER THE SAMPLnK; PERIOD
SAMPLE {xx; 1 IXX; 2 IXG 3 IXG 4 IXG 5 IXG 6 JXG 7 JXG 8 {XX; 9 {XX; 10
Day 1
predose I A I 0.29 :~ : IJ:1IJ I 0.17 , 0.30 I 0.17 1 0.04 I 0.14 : I..CW
I 0.24
I I I I I , 1 I
1 I B I 2.85 I 3.77 I 6.56 I 5.78 I 1.50 I 2.31 I 3.26 I 6.90 I 7.09
I 0.76
2" I I I I I I I I I I
1 I C I 6.19 5.65 I 7.94 I 6.84 I 1.82 , 3.21 I 3.45 I 7.82 I 7.01
I 4.16
I I I I I I I I
I
I 2 , D I 6.02 6.43 1 7.44 I 6.80 , 1.92 I 5.87 I 6.05 I 7.48 I 6.79
I 7.07
I I I I 1 I I I I
I
I.D 4 I E I 5.71 6.10 1 6.30 I 6.90 , 1.81 I 6.67 I 5.88 1 6.82
, 7.58 I 6.80+::> I I I 1 I I I I I
I 6 I F I 5.77 6.01 1 6.43 1 6.60 1 2.01 I 6.60 5.93 I 7.44 I 6.23
I 6.90
I I I I I I I I
I
8 I G I 5.94 6.17 I 6.85 I 6.59 1 1.94 1 6.50 I 6.92 I 7.84 I 6.60
I 6.64, I I I 1 I I I , I
12 I H I 4.98 5.46 I 5.21 I 5.48 I 1.84 I 4.87 I 4.87 I 6.18 I 6.26 6.00I I I I I I I I I
24 I I I 4.43 4.78 I 5.28 I 5.81 I 1.55 1 5.44 1 4.43 I 5.15
I 5.42 I 5.48I I I I I I I I I
I I I I 1 I I
I
I I I I I
, I 1
Day 7 J : 19.72 : 16.42 : 16.63 : 15.89 : 19.74 : 16.86 20.20 I 4.69 : 14.87 : 17.68I
Day 14 I K : 17.36 : 12.69 : 13.92 : 13.41 : 15.71 : 17.12 : 14.21 : 14.02 : 11.22 : 15.54I
Day 21 I L : 15.51 : 12.61 , 7.98 : 11.42 : 13.32 14.99 : 14.09 : 11.51 : 10.11 : 12.89I
TABLE 5A continued•••
SAMPLE In; 1 IXX; 2 {XX; 3 [XX; 4 IXX; 5 IXX; 6 {XX; 7 {XX; 8 IXX; 9 IXX; 10
Day 22
prehours M : 14.16 9.36 11.18 11.02 : 12.83 : 14.74 12.48 12.07 10.00 15.05
1 N : 17.29 15.28 16.55 14.96 : 13.89 : 15.82 10.93 13.98 10.16 15.49"2
1 0 : 19.68 17.60 17.20 18.70 : 15.18 : 16.74 15.16 13.91 12.36 16.80
2 p : 20.24 19.30 17.80 17.93 : 17.13 : 19.96 18.37 16.85 15.52 21.15
4 Q : 21.01 17.84 17.12 17.59 : 19.05 : 20.84 18.69 18.13 16.63 20.22
) 6 R : 20.02 17.71 16.70 17.58 : 19.35 : 20.71 19.74 15.99 15.09 20.35,
.8 S : 20.39 17.16 15.33 19.23 : 18.35 : 19.87 19.12 18.17 15.67 19.83
12 t T : 19.17 : 15.15 13.48 15.15 : 15.73 : 19.91 16.97 15.34 13.27 I 17.92I
24 I U : 14.94 : 11.41 10.87 10.85 : 13.36 : 15.18 13.36 12.13 10.28 : 13.98I
I I I I
I , , ,
Day 24
prehours I V : 14.62 11.65 13.77 9.90 : 13.58 15.37 13.57 : 11.92 9.64 I 12.67I
1 I W : 15.54 12.48 15.27 11.06 : 13.77 16.51 13.17 : 11.66 10.27 15.272" I
1 I X I 15.43 16.51 15.46 11.45 : 13.69 19.55 13.38 : 12.64 13.00 17.42I
2 I Y 14.65 18.26 15.71 14.07 : 13.60 20.57 13.56 : 12.53 15.23 19.46I
4 I z 14.02 16.73 16.45 15.87 : 11.94 17.78 12.47 : 13.29 15.56 19.39I
6 I AA 15.62 16.60 18.18 14.84 : 11.09 17.80 12.69 : .1.4.59 14.93 18.70I
8 I BB 17.87 15.51 17.68 14.80 : 11.15 16.37 14.12 : 16.28 13.77 I 18.17I
12 I cc 16.91 14.54 16.18 13.24 I 9.86 13.55 16.20 : 14.80 13.28 : 16.91I I
24 I DD 15.36 11.87 17.49 11.36 I 8.24 13.60 12.75 : 12.53 10.80 : 14.72I I






Date A H F Medication glven & time
(A = APPETITE H = HABITGS F = FAECES)
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FIGURE 2A:
NUMBER OF DOG: 1 KENNEL NO: 21 COLLAR NO: 160
BREED OF DOG: Labrador X German Shepherd Dog
SEX: Male
COLOUR: Black










DESCRIPTION: Large, lean, placcid temperament.
DAY OBSERVATIONS & PROCEDURES
o 06hOO jugular cath. inserted. Dog weighed. Initial blood
sample taken for base-line. 08hOO dose given with 20ml
water. Blood samples taken by veni-puncture of cephalic as
cath. pulled out at 0,5; 1,0; 2,0; 4,0; 6,0; 8,0; 12,0; &
24hrs post dosing. Serum collected and frozen within 14
hours. No problems. Dog fed at 15hOO.
1 07h45 took blood sample as'above. 08hOO dose given with
water. 15hOO fed. A+++ F+++ W+ H noisy.
2 08hOO dose given in capsule with water. Fed 15hOO.
3 08hOO dose given. HQ ataxia++. A+++F+++W+.Fed 15hOO.
4 08hOO dose given. HQ ataxia+. A+++F+++W+. Fed 15hOO.
5 08hOO dose given. HQ ataxia++. A+++F+++W+H v.quiet. Fed
15hOO.
6 08hOO dose given. HQ ataxia+. A+++F+++W+H+. Fed 15hOO.
7 07h30 blood sample taken and weight recorded. 08hOO dose
given c/w. A+++F+++W+ H quiet & sleeps alot in the sun. Dose
adjusted due to weight gain. Fed at 15hOO.
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8 08hOO dose given c/w. A+++F+++W++ H quiet. Fed 15hOO.
9 08hOO dose given c/w. A+++F+++W+ H alert but quiet. Fed
15hOO.
10 08hOO dose given c/w. A+++F+++W+ H++. Fed 15hOO.
11 08hOO dose given c/w. A+++ F diarrhoea yellow/brown colour
H++. Vomited white bile. Fed 15hOO.
12 08hOO dose given c/w. A+++ F+ W++ H++. Fed 15hOO.
13 08hOO dose given c/w. A+++ F+++ W++ H++. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. Dose adjusted due to weight gain. A+++ F+++ W+++ H++
15 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
16 08hOO dose given c/w. A+++ F+++ W+++ H quiet. Urine normal.
Fed 15hOO.
17 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
18 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
20 08hOO dose glven c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.




NO. OF DOG: 2 KENNEL NO: 20 COLLAR NO: 171
BREED of DOG: Non-Descript (Cross Breed)
SEX: Male
COL09R: Light brown with grey muzzle.
MASS: 16.85kg - 19/1/88 DOSE: 2.75 tabs.(82.5 mg)
16.80kg - 26/1/88 same
17.65kg - 02/2/88 3.00 tabs.(90 mg)
17.25kg - 09/2/BB same
17.75kg - 17/2/88 same
DESCRIPTION: Medium-sized dog. Lean. Placcid. Approx. 9 years.
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1.
1 Blood sample taken at 07h30. OBhOO dose given with water.
A+++F+++W+H noisy. Fed 15hOO.
2 OBhOO dose given in caps. with water. A+++F+++W++. Fed
15hOO.
3 OBhOO dose given in caps. with water. A+++F+++W++H nOlSY.
Fed 15hOO.
4 OBhOO dose given in caps. with water. A+++ F+++ W++ H quiet.
Fed 15hOO.
5 OBhOO dose given c/w. A+++ F+++ W++ H quiet. Fed 15hOO.
6 OBhOO dose given c/w. A+++ F+++ W++ H quiet. Fed 15hOO.
7 07h30 blood sample taken and dog weighed. OBhOO dose given
c/w. A+++ F+++ W+ H quiet. Fed 15hOO.
8 OBhOO dose given c/w. A+++ F+++ W++ H v.quiet/drowsy. Fed
15hOO.
9 OBhOO dose given c/w. A+++ F+++ W++ H alert but v.quiet. Fed
15hOO.
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10 G8hOO dose given c/w. A+++ F+++ W+++ H lively/panting. Fed
15hOO.
11 08hOO dose given c/w. A+++ F+++ W+ H walking slowly/quiet.
Fed 15hOO.
12 08hOO dose given c/w. A+++ F+++ W++ H lively/alert. Fed
15hOO.
13 08hOO dose given c/w. A+++ F+++ W++ H v.alert. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. Dose adjusted due to weight galn. A+++ F+++ W++ H
alert. Fed 15hOO.
15 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
16 08hOO dose given c/w. A+++ F+++ W++++ H v.quiet. Urine ex-
cessive and clear. Fed 15hOO.
17 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Fed
15hOO.
18 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO •
20 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
21 07h30 blood sample taken. OahOO dose glven c/w. Dog weighed.
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FIGURE 2e:
NUMBER OF DOG: 3 KENNEL NO: 19 COLLAR NO: 564
BREED OF DOG: Non-Descript (Cross Breed)
SEX: Male
COLOUR: Brown










DESCRIPTION: Medium, lean, excitable. 11 months.
DAY OBSERVATIONS & PROCEDURES
o As descibed in DOG 1.
1 08hOO dose given with water. A+++W+F+++ H noisy. Fed 15hOO.
2 08hOO dose given in caps. with water. A+++W+F+++ H++.
Fed 15hOO.
3 08hOO dose given c/w. A+++W+F+++ H noisy. Fed 15hOO.
4 08hOO dose given c/w. A+++W+++F+++ H++. Concentrated urine
passed. Fed 15hOO.
5 OahOO dose given c/w. A+++W++F+++ H alert/active. Fed 15hOO.
6 08hOO dose glven c/w. A+++W++F+++ H quiet/alert. Fed 15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H alert/ licking paws. Fed 15hOO.
8 08hOO dose given c/w. A+++ F+++ W+++ H v.quiet & sleepy. Fed
15hOO.
9 08hOO dose given c/w. A+++ F diarrhoea
v.quiet/panting. Urine v.clear. Fed 15hOO.
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10 08hOO dose given c/w. A+++ F+ W+ H boisterous. Fed 15hOO.
11 08hOO dose given c/w. A+++ F+++ W+ H panting alot/ lively &
friendly/ excitable. Fed 15hOO.
12 08hOO dose given c/w. A+++ F+++ W+ H lively/ v.alert.
Fed15hOO.
13 08hOO dose given c/w. A+++ F+++ W+ H quiet but alert. Fed
15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H quiet but alert. Urine clear. Fed 15hOO.
15 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO .
16 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
17 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
18 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W+++ H quiet but normal. Fed
15hOO.
20 08hOO dose given c/w. A+++ F+++ W+++ H quiet but v.alert.
Urine normal. Fed 15hOO.
21 07h30 blood sample taken. 08hOO dose given c/w. Dog weighed.
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FIGURE 20:
NUMBER OF DOG: 4 KENNEL NO: 18 COLLAR NO: 51
BREED OF DOG: Fox Terrier X Collie
SEX: Male
COLOUR: White with black spots










DESCRIPTION: Medium, lean, excitable. Age 2 years.
DAY OBSERVATIONS & PROCEDURES
o As described for DOG 1.
1 08hOO dose given with water. A+++ W+ F- H active. Fed 15hOO.
2 08hOO dose given ln caps. with water. A+++W+F+++ H v.active.
Fed 15hOO.
3 08hOO dose given c/w. A+++ W++F+++ H active/noisy. Fed
15hOO.
4 08hOO dose given c/w. A+++ W++ F++ H ++. Fed 15hOO.
5 08hOO dose given c/w. A+ W++ F khaki-coloured & soft H++.
Fed 15hOO. Still had remaining pellets from previous nights
feed but removed before medication.
6 08hOO dose given c/w. A+ W++ F still loose/khaki. T=38.7°C.
Fed 15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H quiet. HQ ataxia +. Fed 15hOO.
8 08hOO dose given c/w. A+++ F soft with TAPEWORM W+ H+
T=39.3°C. Dog has a purulent occular discharge. Fed 15hOO.
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9 08hOO dose given c/w. A+ F+ W+ H v.quiet. T=39.2°C. still
has occular discharge from R eye. Fed 15hOO.
10 08hOO dose given c/w. A++ F++ W++ H quiet. Fed 15hOO.
11 08hOO dose given c/w. A+++ F+++ W++ H v.v.excitable.
T=38.5°C. Fed 15hOO.
12 08hOO dose given c/w. A+++ F+++ W++ H v.excitable & lively.
T=38.6°C. Fed 15hOO.
13 08hOO dose given c/w. A+++ F+++ W++ H alert but quiet. Oc-
cular discharge again. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W++ H quiet. Urine normal. Fed 15hOO.
15 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
16 08hOO dose given c/w. A+++ F+++ W+ H quiet but alert. Urine
normal. Fed 15hOO.
17 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
18 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
20 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
21 07h30 blood sample taken and dog weighed. 08hOO dose given.
-104-
FIGURE 2E:
NUMBER OF DOG: 5
BREED OF DOG: Bull Terrier
SEX: Male
KENNEL NO: 17 COLLAR NO: 689
COLOUR: Black with white & tan










DESCRIPTION: Medium, well muscled, excitable, needle-shy.
Age approx. 2 years.
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1.
1 08hOO dose given with water. A+++ W++ F+ H quiet but alert.
Fed 15hOO.
2 08hOO dose given in caps. with water. A+++ W++ F putty-
coloured and loose. stool examined but NAD. H++. Fed 15hOO.
3 08hOO dose given c/w. A+++ W++ F++(normal) H quiet. Passed
concentrated urine. Fed 15hOO.
4 08hOO dose given c/w. A+++ W+ F+++ H++. Fed 15hOO.
5 08hOO dose given c/w. A+++ W++ F+++ H boisterous but later
quieter. Fed 15hOO.
6 08hOO dose given c/w. A+++ W++ F+++ H boisterous. Fed 15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. Dose adjusted due to weight loss. A+++ F+++ W+ H quiet.
Fed 15hOO.
a OahOO dose given c/w. A+++ F+++ W+ H quiet but alert. Fed
15hOO.
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9 OahOO dose given c/w. A+++ F+++ W+ H quiet but alert. Fed
15hOO.
10 OahOO dose given c/w. A+++ F+++ W+ H panting but lively. Fed
15hOO.
11 OahOO dose given c/w. A+++ F+++ W++ H alert/ v.lively/ pant-
ing alot -(hot day). Fed 15hOO.
12 OahOO dose given c/w.' A+++ F+++ W++ H lively. Fed 15hOO.
13 OahOO dose given c/w. A+++ F+++ W++ H alert but quiet. Fed
15hOO.
14 07h30 blood sample taken and dog weighed. OahOO dose given
c/w. A+++ F+++ W++ H quiet but v.alert. Urine normal. Fed
15hOO.
15 OahOO dose given c/w. A++ F+++ W++ H quiet but v.alert.
Urine normal. Fed 15hOO.
16 OahOO dose given c/w. A+++ F+++ W+++ H quiet but v.alert.
Urine normal. Fed 15hOO.
17 OahOO dose given c/w. A+++ F+++ W++ H quiet but v.alert.
Urine normal. Fed 15hOO.
la OahOO dose given c/w. A+++ F+++ W++ H quiet but v.alert.
Urine normal. Fed 15hOO.
19 OahOO dose given c/w. A+++ F+++ W++ H quiet but v. alert.
Fed 15hOO.
20 OahOO dose given c/w. A+++ F+++ W++ H quieter but still
alert. Urine normal. Fed 15hOO.




NUMBER OF DOG: 6
BREED OF DOG: Mastiff X
SEX: Male
COLOUR: Brown with white
KENNEL NO: 15 COLLAR NO: 264










DESCRIPTION: Large, thin, placcid. Age uncertain (± 6 years).
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1.
1 08hOO dose given with water. A+++ W+ F+++ H quiet. Fed
15hOO.
2 08hOO dose given in caps. with water. A++ W+ F+++ H v.quiet-
T=39,7°C. Fed 15hOO.
3 08hOO dose' given c/w. T=39,5°e. Blood smear shows WBe in-
crease esp. N+++(immatures). Suspect reaction locally at
multiple veni-puncture site. Inject 3cc Duplocillin i/m.
A+++ W++ F+++ H v.quiet. Fed 15hOO.
4 08hOO dose given c/w. T=39,5°C. Walking okay. A+++ W++ F+++
H+. Fed 15hOO.
5 08hOO dose given c/w. T=39,0°C. Happy dog. A+++ W++ F+++ H
v.quiet. Fed 15hOO.
6 08hOO dose given c/w. A+++ W++ F+++ H+. Fed 15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H quiet. Fed 15hOO.
8 08hOO dose given c/w. A+++ F+++ W++ H v.quietl appears
slightly weak. Urinatlng normal. Fed 15hOO.
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9 08hOO dose given c/w. A+++ F+++ W+ H quiet but alert. Fed
15hOO.
10 08hOO dose given c/w. A+++ F+++ W+ H panting but appears
fine. Fed 15hOO.
11 08hOO dose given c/w. A+++ F+++ W++ H quieti lethargic. Fed
15hOO.
12 08hOO dose given c/w. A+++ F+++ W++ H good. Fed 15hOO.
13 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose glven
c/w. A+++ F+++ W+++ H quiet but alert. 'Urine normal. Fed
15hOO.
15 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
16 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
17 08hOO dose given c/w. A+++ F+++ W++ H alert. Urine normal.
Fed 15hOO.
18 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
20 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.




NUMBER OF DOG: 7 KENNEL NO: 14 COLLAR NO: 75
BREED OF DOG: Bull Dog X Ridgeback
SEX: Male
COLOUR: Tan










DESCRIPTION: Medium, barrel-framed, lean. Age 8 years.
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1. Dog however becomes viscious when
forcing tablets down. Therefore tabs. given in a tiny piece
of mince which it takes readily.
1 08hOO dose given in meat. No water is given but tabs. well
swallowed. A+++ W+ F+++ H quiet. Fed 15hOO.
2 08hOO dose given in caps. 1n meat. A+++ W+ F- H quiet. Fed
15hOO.
3 08hOO dose given elm. A+++ W++ F- H quiet. Fed 15hOO.
4 08hOO dose given elm. A+++ W++ F+ H quiet. Passed con-
centrated urine. Fed 15hOO.
5 oahOO dose given elm. A+++ W++ F+++ H quietlsleeps alot. Fed
15hOO.
6 OahOO dose given elm. A+++ W++ F+++ H quiet. Licking paws.
Fed 15hOO.
7 07h30 blood sample taken anddog weighed. OahOO dose given
elm. A+++ F+++ W+ H quieti resting. Fed 15hOO.
a OahOO dose given elm. A+++ F+++ W++ H v.lethargicl appears
weak. Urinating normal. Fed 15hOO.
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9 08hOO dose given elm. A+++ F+++ W+ H alert & bright. Urinat-
ing normal. Fed 15hOO.
10 08hOO dose given elm. A+++ F+++ W+ H quiet but alert. Fed
15hOO.
11 08hOO dose given elm. A+++ F+++ W++ H quieti walking slowly.
Fed 15hOO.
12 08hOO dose given elm. A+++ F+++ W++ H++. Fed 15hOO.
13 08hOO dose given elm. A+++ F normal but has TAPEWORM W++ H
quiet but alert. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
elm. A+++ F+++ W++++ H v.quiet. Fed 15hOO.
15 08hOO dose given elm. A+++ F+++ W+ H quiet but alert. Urine
normal. Fed 15hOO.
16 08hOO dose given elm. A+++ F+++ W+++ H v.quiet. Urine nor-
mal. Fed 15hOO.
17 08hOO dose given elm. A+++ F+++ W+++ H alert. Urine normal.
Fed 15hOO.
18 OahOO dose glven elm. A+++ F+++ W++ H quiet. Urine normal.
Fed 15hOO.
19 08hOO dose given elm. A+++ F+++ W+++ H quiet. Fed 15hOO.
20 08hOO dose given elm. A+++ F+++ W+++ H quiet. Urine normal.
Fed 15hOO.




NUMBER OF DOG: 8 KENNEL NO: 12 COLLAR NO: 636
BREED OF DOG: Staffie X Labrador
SEX: Female
COLOUR: Brindle & black










DESCRIPTION: Medium, well muscled, excitable, Age 1 year.
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1.
1 08hOO dose given with water. A+++ W+ F- H noisy. Fed 1ShOO.
2 08hOO dose given in caps. with water. A+++ W++ F+++ H nOlsy.
Fed 1ShOO.
3 08hOO dose given c/w. A+++ W++ F+++ H noisy. Fed 1ShOO.
4 08hOO dose given c/w. A+++ W+ F- H quiet. Fed 1ShOO.
5 08hOO dose given c/w. A+++ W++ F soft H noisy. Fed 15hOO.
6 08hOO dose glven c/w. A+++ W++ F+++ H noisy. Fed 15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H v.quiet. Fed 15hOO.
8 08hOO dose given c/w. A+++ F normal but has TAPEWORM W+++ H
v. quiet. Urinating normal. Fed 15hOO.
9 08hOO dose given c/w. A+++ F+++ W++ H++. Fed 1ShOO.
-111-
DOG 8 CONT/ PAGE 2
10 08hOO dose given c/w. A+++ F+++ W+ H panting alot/ v.quiet.
Fed 15hOO.
11 08hOO dose given c/w. A+++ F+++ W++ H alert & lively. Fed
15hOO.
12 08hOO dose given c/w. A+++ F+++ W+++ H boisterous. Fed
15hOO.
13 08hOO dose given c/w. A+++ F+++ W++ H v.alert. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+++ H quiet. Urine normal. Fed 15hOO.
15 08hOO dose given c/w. A+++ F+++ W++ H alert. Fed 15hOO.
16 08hOO dose given c/w. A+++ F+++ W++ H v.alert. Urine normal.
Fed 15hOO.
17 08hOO dose given c/w. A+++ F+++ W+++ H alert. Urine normal.
Fed 15hOO.
18 08hOO dose given c/w. A+++ F+++ W++ H quiet but v.alert.
Urine normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert.
Fed 15hOO.
20 08hOO dose given c/w. A+++ F+++ W++ H quiet but v.alert.
Urine normal. Fed 15hOO.
21 07h30 blood sample taken and dog weighed. 08hOO dose given.
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FIGURE 21:
NUMBER OF DOG: 9 KENNEL NO: 13 COLLAR NO: 455
BREED OF DOG: GERMAN SHEPHERD DOG (GSD)
SEX: Female
COLOUR: Black & Tan










DESCRIPTION: Large, thin, placcid. Age uncertain (± 2 years)
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1.
1 08hOO dose given with water. A+++ W+ F- H quiet. Fed 15hOO.
2 08hOO dose given in caps. with water. A+++ W+ F+ H quiet.
Fed 15hOO.
3 08hOO dose given c/w. A+++ W+ F+ H noisy. Fed 15hOO.
4 08hOO dose given c/w. A+++ W+ F+++ H restless. Fed 15hOO.
5 08hOO dose given c/w. A+++ W+ F+++ H quiet. Fed 15hOO.
6 08hOO dose given c/w. A+++ W++ F+++ H noisy. Fed 15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H quiet. Fed 15hOO.
8 08hOO dose given c/w. A+++ F+++ W++ H drowsy. Urinating nor-
mal. Fed 15hOO.
9 08hOO dose given c/w. A+++ F+++ W+ H alert. Fed 15hOO.
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10 08hOO dose given c/w. A+++ F+++ W+ H panting a lot/ lethar-
gic. Fed 15hOO.
11 08hOO dose given c/w. A+++ F+++ W++ H alert. Fed 15hOO.
12 08hOO dose given c/w. A+++ F+++ W+ H v. alert. Fed 15hOO.
13 08hOO dose given c/w. A+++ F+++ W++ H alert. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. Dose adjusted due to weight gain. A+++ F+++ W+++ H
quiet but alert. Fed 15hOO.
15 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
16 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
17 08hOO dose given c/w.-A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.
18 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert.
Urine normal. Fed 15hOO.
19 08hOO dose given c/w. A+++ F+++ W+++ H quiet but alert. Fed
15hOO.
20 08hOO dose given c/w. A+++ F+++ W++ H quiet but alert. Urine
normal. Fed 15hOO.




NUMBER OF DOG: 10
BREED OF DOG: Doberman
SEX: Male
COLOUR: Black with tan
KENNEL NO: 11 COLLAR NO: 118










DESCRIPTION: Large, thin, placcid. Age 8 years.
DAY OBSERVATIONS & PROCEDURES
o As described in DOG 1.
1 08hOO dose given with water. A+++ W+ F++ H noisy. Fed 15hOO.
2 08hOO dose given in caps. with water. A+++ W+ F+++ H drowsy,
seems to cross-over hind legs, looks bewildered. Fed 15hOO.
3 08hOO dose given c/w. A+++ W+ F+++ H scrapes hind feet when
walking, paws appear puffy, otherwise quiet. Fed 15hOO.
4 08hOO dose given c/w. A+++ W+ F++ H quiet, walking better,
not so inco-ordinated, paws still puffy. Fed 15hOO.
5 08hOO dose given c/w. A+++ W+ F++ H v.quiet, knuckling and
scraping hind paws when walking. Fed 15hOO.
6 08hOO dose given c/w. A+++ W+ F+++ H v.quiet T=39,0°C. Fed
15hOO.
7 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+ H v.quiet/ drowsy. Fed 15hOO.
8 08hOO dose given c/w. A+++ F+++ W+++ H weak T=40.8°C.
Urinating normal. Fed 15hOO.
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9 08hOO dose given c/w. A+++ F+++ W+++ H alert/ brighter
T=38.4°C. Fed 15hOO.
10 08hOO dose given c/w. A+++ F+++ W++ H v.quiet. Fed 15hOO.
11 08hOO dose given c/w. A+++ F+++ W+ H lethargic. Fed 15hOO.
12 08hOO dose given c/w. A+++ F+++ W++ H v.quiet. Occular
purulent discharge. Fed 15hOO.
13 08hOO dose given c/w. A+++ F+++ W+ H quiet. Discharge
stopped. Fed 15hOO.
14 07h30 blood sample taken and dog weighed. 08hOO dose given
c/w. A+++ F+++ W+++ H quiet. Fed 15hOO.
15 08hOO dose given c/w. A+++ F+++ W+++ H quiet. Fed 15hOO.
16 08hOO dose given c/w. A+++ F+++ W+ H quiet. Urine normal.
Fed 15hOO.
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Table 6 Absorption rate constant (KA ) and elimination rate constant (Ks )
for the dogs in the phenobarbitone pharmacokinetic trial for
Day 1, Day 22, and Day 24
K,A. KE
DOG NO I DAY 1 I DAY 22 I DAY 24 DAY 1 DAY 22 DAY 24I I I
1 , 1.71 I 0.08 0.26 0.017 0.019 0.015I I
2 I 1.82 I 1.34 1.03 0.014 0.029 0.021I I
3 I 4.00 I 2.73 0.51 0.019 0.049 0.008I ,
I 4 I 3.64 I 1.28 0.44 0.010 0.025 0.032~ I I I
~ 5 2.58 0.43 1.30 0.009 0.024 0.025
~
I 6 0.79 0.36 1.76 0.015 0.022 0.020
7 0.99 0.50 I 1.13 0.019 I 0.028 0.034
8 4.00 0.50 I 0.52 0.017 , 0.022 0.037I I
9 9.81 0.50 I 0.62 0.012 I 0.030 0.024I I
10 0.76 0.58 I 1.23 0.017 I 0.021 0.024I I
ti'
TABLE 8: THE ELIMINATION HALF-LIFE CALCULATED FOR EACH
DOG FOR DAY 0 AND DAY 22












... full dosage on day 0 suspect
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TABLE 9 : AREA UNDER CURVE VALUES FOR THE DOGS FOR
DAY 22 AND DAY 24 CALCULATED BY THE
LINEAR TRAPEZOIDAL RULE














TABLE 10: PEAK AND TROUGH SERUM CONCENTRATIONS (lJg.m1-:l.)
FOR PHENOBARBITONE AT STEADY STATE IN HEALTHY DOGS
(N=10)
DOG No. tmax Cmax Cmin Cmax-Cmin
1 8hr 17.87 14.02 3.8S
2 2hr 18.26 11.65 6.61
3 6hr 18.18 13.77 4.41
4 4hr 15.87 9.90 5.97
5 0,5 13.77 8.24 5.53
6 2hr 20.57 13.55 7.02
7 12hr 16.20 12.47 3.73
8 8hr 16.28 11.66 4.62
9 4hr 15.56 9.64 5.92
10 2hr 19.46 12.67 6.79
X 4.85 17.20 11.75 5.44 ( :t 1 .22 )
tmax = time to peak serum concentration
Cmax = maximum serum concentration






AT STEADY-STATE WITHOUT FOOD
DOG 1
PHENOBARBITONE SERUM CONCENTRATIONS














10 t-- I 10
252015105
5' · , I , •
o252015105
5' I I I I I
o
TIME (hours) TIME (hours)
+ MEASURED - PREDICTED + MEASURED - PREDICTED
FIGURE 38
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 2
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 3C
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 3
PHENOBARBITONE SERUM CONCENTRATIONS















10 I- I 10
252015105
5' I I I I ,
o252015105
5' , I I I I
o
TIME (hours) TIME (hours)
+ MEASURED - PREDICTED + MEASURED - PREDICTED
FIGURE 3D
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 4
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 3E
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 5
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 3F
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 6
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 3G
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 7
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 3H
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 8
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 31
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 9
PHENOBARBITONE SERUM CONCENTRATIONS
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FIGURE 3J
PHENOBARBITONE SERUM CONCENTRATIONS
AT STEADY-STATE WITHOUT FOOD
DOG 10
PHENOBARBITONE SERUM CONCENTRATIONS
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APPENDIX C
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FIG 6: CANINE EPILEPSY DATA FORM
VETERINARY HOSPITAL: __
NAME OF DOG: _




FSEX: : ~1-_--:....---:MTHSYRAGE: :
MASS: BREED:------
CONCCRRENT ILLNESS: : Y : N 'Specify: __




DATE SERUM CONC.: WITH
COMMENCED: ug/ml MEALS
TIME AND DATE OF LAST DOSE:
TIME OF LAST SAMPLE:
Concurrent ~edication during last month
DRUG DOSE DATE COMMENCED
CLINICAL PHARMACOKINETICS LABORATORY
DEPARTME~T OF PHARMACOLOGY




































AGE : MASS SEX DOSE (mg) : SERUM CONC·
(yrs): (kg) : (l1g.ml-.1.):..----=-- _
14 '4.5 F 30 : 16.56
10 4 F 60 : 24.52
12 4 F 15 : 17.76
2 3.5 F 60 : 28.74
12 7 M 60 I 21.68
6.5 14 F 45 29.74
4 6 M 45 14.54
4 6 M 60 31.89
10 8 F 30 17.79
10 8 F 60 32.3
10 8 F 90 48.64
8 F 210 74.57
28 F, 30 2.31
28 F: 60 5.26
7 M 30 16.8
7 M 60 26.87
7 M 180 70.47
80 ,M 300 23.16
5.5 : F 30 12.64
7 : F 30 18. 71
1 : MIN DOB
2 : PEKE









9 : NDS DOG
10 : DOB
DOB
11 : MIN DOB
MIN DOB
MIN DOB
12 : ST BERNARD
13 : MALTESE X
14 : FOX T X
PATIENT NO: SPECIES
* = measured serum concentration
Table 13: The prediction error between the predicted and
the observed concentration in the ~pileptic dogs
DOG NO : DOSE GIVEN I PREDICTED CONC OBSERVED CONC : PREDICTED ERRORI
(mg.kg- 1 ) I (lJg.ml- 1 ) (pg.ml- 1 )I, I I
I
1 6.7 20.99 16.56 , -4.43
2 15 46.99 24.52 -22.47
3 3.75 11.75 17.76 +6.01
4 17.1 53.57 28.74 -24.83
I 5 8.6 26.94 21.68 -5.26
t--' 6 3.2 10.02 29.74 +19.72lA)
(.Jl 7 7.5 23.49 14.54 +8.95I
8 10 31.33 , 31.89 +0.56
9 3.75 11.75 17.79 +6.04
10 7.5 23.50 32.3 +8.80
11 11.2 35.09 48.64 +13.55
12 26.2 82.08 74.57 -7.51
13 1.1 3.45 2.31 -1.14
14 22.2 6.89 5.26 -1.63
15 4.3 13.47 16.8 +3.33
16 8.6 26.94 26.87 -0.07
17 25.7 80.51 70.47 -10.04
18 3.75 11.75 23.16 +11.41
19 5.5 17.23 12.64 -4.59
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ABSTRACT
The pharmacokinetics of oral phenobarbitone was studied in 10
clinically healthy adult dogs. The drug was given once daily in tablet
form, at a dose of 5 mg kg- 1 of body mass. Serial venous blood samples
(n =9) were collected from each dog on Day 1 (the first day of drug dos-
ing), on Day 22, and on Day 24 after continuous dosing. Trough serum
concentrations were determined on Day 7, Day 14 and Day 21. The
drug was administered to the dogs on an empty stomach, except on Day
24, when it was given with food, in order to assess the influence of food
on its absorption. Drug serum concentrations were described by a one-
compartmental open model with first order absorption and elimination.
An average steady-state trough serum level of phenobarbitone of 52,96
± 8,40 mmol i-I was achieved after 3 weeks of daily dosing. The mean
elimination half-lives for Day 1 and Day 22 were 46,3 ± 11,3 hand
29,3 ± 4,6 h respectively. The area under the curve for Day 22 was
1 656,17 ± 186,45 J,Lmol h-l f-I and for Day 24 was 1 493,06 ± 205,4
J,Lmol h -1 i-I. The mean clearance value for Day 22 was 0,0133 ±
0,0016 i h -I kg-I. Side effects of polyphagia, polydipsia, sedation and'
ataxia were commonly observed in the first 2-9 d, but disappeared
thereafter.
It was concluded that a dose of 5 mg kg- I would achieve an average
serum concentration of 64,59 J,Lffiol i-I in adult dogs. Once daily dosing
should be adequate, since relatively small peak-through fluctuations
were observed (27,6 J,Lmol i-I). The dose may be given with food for
convenience, even though the extent of absorption is approximately
10% less than when given on an empty stomach. If the 10% difference
is considered clinically significant, the dose can be adjusted accordingly.
Dosing should continue unchanged for at least 3 weeks to allow enzyme
induction to settle and to achieve steady-state before adjusting doses
based on serum concentrations.
INTRODUCTION
Seizure disorders are amongst the most
frequently seen neurological problems in
small animal practice. Seizures often pre-
sent a diagnostic dilemma because they
• Biomedical Resource Ccm~e. l- niversl:v of Durban- \'rc:st-
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are episodic, frequent Iv not observed bv
the veterinarian and oft"en present with n~
other clinical abnormality. Seizures, epi-
lepsy, fits or convulsions have been des-
cribed as collective terms used to describe
a disorder of brain function characterised
by paroxysmal, stereotyped alterations in
behaviour3• The term epilepsy indicates
that the seizures are recurring, but does
not imply the cause of the seizures. The
most common form of epilepsy in the dog
presents as a tonic-clonic seizure, with
petit-mal and Jacksonian forms of
seizures being rarely diagnosed3.
Epileptic'seizures in dogs may be con·
trolled by a variety of drugs, the mOSi
common of 'which is phenobarbitom
alone or in combination with other anti·
convulsant drugs which is administerec
orally' .
Barbiturates were the first class oJ
drugs to be used for treatment of epilep·
sy. Phenobarbitone was first introduced
as an effective anticonvulsant in 1912:
providing therapeutic control against
most varieties of seizures except absence
(petit-mal) seizures6 •
In order to achieve a reasonable thera-
peutic effect without marked adverse ef-
fects in man, phenobarbitone plasma con-
centrations of 40 to 110 J.Lmol f-l are con-
sidered necessary'. In order to achieve a
therapeutic plasma level, the recommen-
ded oral maintenance dose of phenobarbi-
tor e in adults and adolescents is from 1.5
to 2 mg kg- l per day!. Infants and chil-
dn:n require approximately twice the
adult dosage, or 3 to ·t5 mg kg-I per day:
because they clear the drug faster than
adults!. Because of its long half-life in
man, dosing once daily at bedtime is ade-
quate in most patients. It requires 2-3
weeks (5 half-lives) for phenobarbitone to
reach steady-state therapeutic levels in
man.
The control of epileptic seizures in
dogs is, however, not as well-described as
is the case in man. The literature offers
dosage ranges for dogs of 2 to 20 mg kg- l
phenobarbitone per dav which may be
divided into twice dail; or even 3 times
daily dosing, or given '''to effect"3 '. As
phenobarbitone requires only once daily
administration in man because of its long
half-life (50-120 hours), it would there-
fore appear that, in dogs, the clearance of
phenobarbitone is more rapid than in hu-
mans.
The purpose of this study was to moni-
tor and evaluate pla3ma serum phenobar-
bitone concentrations over a period of 3
weeks on daily dosing. The effect of food
on the absorption of the drug was also in-
vestigated.
MATERIALS AND METHODS
Ten adult dogs of mixed breeds and sex
were selected for the purpose of the drug
trial (Table 1).•1\11 were short-haired and
without excess body fat. Two weeks prior
to commencement of the trial, the dogs
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Cl = F x dose/Al:C (e hr- 1 kg-I) (2)
Analysis of variance was used on the
half-life and ACC values in order to test
variation between subjects and also be-
The area under the curve (AUC) was cal-
culated by the linear trapezoidal rule.
The total body clearance at steady state
can be calculated in a model-independent
fashion by using the following equation:
DISCUSSION
Phenobarbitone distributes into most
body tissues fairly rapidly, permitting the
87
RESULTS
A one-compartment open model was ade-
quate to describe the data. Calculated
pharmacokinetic values indicating the ab-
sorption, accumulation and excretion of
PHB from Days 1, 22 and 24 are presen-
ted in Table 1 and Fig. 1. On Day 1 there
was a fairly rapid absorption ofPHB with
average peak serum concentrations of
28.03 ± 2.8-4 ,umol [-1 occurring 2 h after
dosing. Absorption rate constants (Table
2) showed a large variation.
Serum levels measured on Day 22,
showed a trough concentration of 52.96
± 8.40 ,umol e- I. Following drug
administration, there was again a fairly
rapid absorption with an average peak
concentration of 80.52 ± 6.63 ,umol e- l
attained within 2 to 4 h of dosing.
Following Day 1, there was a slow accu-
mulation in the PHB plasma concentra-
tion followed by a decline to a stable
trough level of 52.96 ± 8.18 ,umol e-!
which occurred 22 d from commence-
ment of initial dosing (Fig. 2).
The mean elimination half-life (tl/,) for
Day 1 was 46.3 ± 11.3 h and for Day 22
it was 29.3 ± 4.6 h. The results are given
in Table 2. Dog 5, a bull terrier, could
not be used in this comparison as there
was doubt as to the dose it had received
on Day 1. The results obtained were com-
pared by two-way analysis of variance,
which -showed that there was no signifi-
cant difference between sub jects
(P < 0.5), but there was a significant dif-
ference between Day 1 and Day 22
(P < 0.0066).
The area under the curve (ACC) is a
measure of extent of drug absorption if
clearance is COllstant. A difference of ap-
proximately 10% in the .-\CC was found
when Day 22 and Day 2-4 were compared
(P = 0.0496), suggesting that a lesser
amount of the drug had been absorbed
when given with the food (Table 2).
The mean clearance value for the sam-
ple group on Day 22, was 0.0133 ±
0.0016 fh- 1 kg-to
The majority of dogs showeg mild to
moderate side-effects to the drug. The
side-effects of polyphagia, polydipsia and
sedation were initiallv observed from Dav
2 in all test animals.' In addition, 3 dogs
showed hindquarter ataxia. All these side-
effects, however, were of short duration
and were no longer evident by Day 10.
All haematological and biochemical para-
meters measured remained within normal
physiological limits and no significant
changes were recorded.
tween tre:ltme:lts (P < 0,05 t:lken to be
significant).
(1 )
and placed into capped test tubes without
anti-coagulant (Venoj ect-plain). The
serum was separated by centrifugation at
1 500 rpm for 5 min at 20°C and then
stored at -20°C until assayed for PHB
concentration.
The animals were monitored daily for
signs of poor health or side-effects, in par-
ticular for polyphagia, polydipsia, poly-
uria, sedation, ataxia, and hyperkinesis
which have been rep'orted in the litera-
ture' ;.
The concentration of phenobarbitone
~n the serum samples was determined, us-
ing the TDx System which uses the
fluorescence polarisation immunoassay
(FPlA) technology (Abbot Laboratories
Diagnostic Division~ Irving Texas, Uni-
ted States of America).
The serum concentration time pairs for
each dog were fitted for single dose,
steady state without food, and steady state
with food using nonlinear least squares
regression (STATIS (Version 2.1) 1987
Aydesoft statistical and scientific soft-
ware, Larkhall). A one- and a two-com-
partment open model were compared for
effectiveness of fit by the residual sum of
squares and Akaike's Information
Criterion (AIC)9. Estimations of the
absorption rate constant (K ) and the
elimination rate constant (K .-\) were ob-
tained. E
The first-order elimination constant
(K.E) :vas ~sed to calcul~te the biological
half-hfe usmg the followmg equation:
Table 1: Breed, sex, age, body mass and condition of ex-
perimental dogs
No. Breed Sex Age Mass Condition
(yrs) (kg)
1 Lab. X G.S.D. ~i -4 24 lean
2 Mixed M 9 17 lean
3 iVlixed Ni 1 15 lean
4 Fox Terrier X iVi 2 24 lean
5 Bull Terrier M 2 23 well-muscled
6 Mastiff X M 7 23 lean
7 Bull iViastiff X Ni 8 28 lean
8 Lab. X Bull Terrier F 1 19 well-muscled
9 G.S.D. F 2 22 lean
10 Doberman M 8 27 lean
M = Male; F = Female; X = Mixed breed.
were examined and evaluated for tracta-
bility and clinical soundness. This in-
volved recording the body mass of each
animal, a thorough physical examination,
and the collection of venous blood for
haematological and biochemical screen-
ing (full blood count, plasma (P)-glucose,
serum (S)-urea, serum (S)-creatinine, ala-
nine transaminase (ALT), serum (S)-bili-
rubin, serum alkaline phosphatase (ALP),
total serum proteins (S-TSP), serum
(S)-albumin and serum (S)-globulins).
Animals showing any deviation from the
accepted norm, were excluded from the
test group. The selected animals were in-
oculated and dewormed in accordance
with standard veterinary preventive
medicine and quarantined individually in
kennels for a period of 2 weeks prior to
the study. For the duration of the drug
trial, the animals were provided with
water ad lib. and were fed dry commer-
cial, pelleted dog food daily at 15:00.
Following the quarantine period, the
dogs were again clinically examined for
soundness and their mass was recorded.
Sodium phenobarbitone (PHB) (Lethyl,
Lennon Laboratories, 30 mg per tablet)
was administered orally in tablet form at a
dosage rate of 5 mg kg- 1 ofbody mass per
day. It was administered with 20 ml tap
water to all the dogs on an empty stomach
at 08:00 each day, until the last day of the
trial. On Day 24, food was given directly
after dosing, in order to evaluate the ef-
fects of food on drug absorption, as this
would probably simulate the clinical
situation.
On Day 1 (the first day of drug dosing),
Day 22 (empty stomach) and Day 24
(with food), serial venous blood samples
(n=9) were withdrawn from the jugular
vein, over a 24 h period following drug
administration (i.e. at 0,5; 1; 2; 4; 8; 12;
and 24 h after dosing). On Day 7, 14, and
21, one blood sample was withdrawn
from the cephalic vein just prior to closing
(i.e. trough-level). All blood samples were
withdrawn into sterile, dry 3 ml syringes




h h- 1 h- I ,umol h e- I eh -I kg- I ,umol ,'-I
Day Day Day Day Day Day Day Day Day Day
1 22 1 22 1 22 22 24 22
22
MEAN 46.3 29.3 3.0085 0.9068 0.0156 0.0242 1656.17 1493.06 0.0133
27.60
SD 11.31 4.6 2.7085 0.7287 0.0032 0.0036 186.45 205.4 0.0016
7A9
CV% 24.4 15.7 90.02 80.35 20.5 14.9 11.3 13.8 12.0
27.18
AC = average peak - trough serum concentrations
p
100 --------------
Dose = Cl/F x er x Dosing Interval x
0.232 (3)
U sing the above equation, therefore, indi-
cates that a dose of 5 mg kg- I 24 h- I
should maintain an average serum con-
centration in the region of 65 ,umol e- i
which is within the therapeutic range de-
termined in man (40-110 ,umol e- i)1 S ~.
Further studies are being undertaken to
determine the therapeutic range in epilep-
tic dogs.
The small fluctuation in the serum con-
centration (ACp) as shown in Table 2,
combined with the relatively long t 1/,
(29,3 ± 4.6 h) would support that once
daily dosing is probably adequate to
maintain reasonable therapeutic effects.
This would then enhance owner com-
pliance, thus hopefully achieving better
epileptic control.
In conclusion, our recommendations
subject to determination of the thera-
peutic range in dogs, are as follows:
It therefore is apparent that 3 weeks of
daily dosing is required before enzyme in-
duction is complete (14 d at least) and
steady state at a constant clearance can be
achieved.
Since phenobarbitone was not adminis-
tered intravenously, it was not possible to
estimate the relative bioavailability (F) of
oral phenobarbitone. Clearance in this
situation is therefore more correctly term-
ed oral clearance, since it includes the
oral bioavailability factor (Cl/F). In
humans and dogs, bioavailability has
been shown to be essentially complete
(88-100%)2 -\. Oral clearance (ClIF) will
therefore closely approximate total body
clearance (C 1).
Clearance of phenobarbitone in dogs
was calculated as 0.0133 ± 0.0016 f h-:
kg- I which is more than 4 times that for
humans (0.0032 eh- i kg-!)I. L"sing oral
clearance, the following equation can be
used to calculate a dose for a desired con-
centration (Cp)' [Note 0.232 is the con-





1: Average serum phenobarbito-
ne concentrations in dogs for
the initial day of dosing (Day
1), 22 days after dosing (Day
22) and after the intake of food
on Day 24
In general, a difference of less than 200/0
is considered to be bio-equivalents.
Therefore it is unlikely that feeding and
simultaneously dosing the animals, will
have a clinically significant effect on the
control of epilepsy in the dog.
In this particular study, the mean
elimination half-life of phenobarbitone
sodium declined from 46.3 ± 11.6 h calcu-
lated for Day 1, to 29.3 ± 4.6 h after 3
weeks of daily oral dosing. It is as-
sumed that this decline is due to mi-
crosomal en.zyme inductionS 7. The initial
rise in trough levels from Days 1 to 7 and
the decline and stabilisation by 3 weeks,
0-------------- supports this assumption. Both the initial
o 4 12 16 20 24 and final half-lives in this study were con-
siderably shorter than those reported in a
single dose study by Pedersoli et al.4,
where the t l /, for oral dosing was 72.3 ±
15.5 h. The half-life of 53.0 ± 15 h
reported in another study5 after 5 d of oral
dosing, is comparable to the initial half-
life reported in this study. Five d is pro-
bably not long enough for enzyme induc-
tion to reach a maximum. Another possi-
ble reason for the relatively short half-
lives found in the present study could be
the relatively short sampling interval of
only 24 h after dosing, whereby distribu-
tion may still be operative. The other stu-
dies sampled over 288 and 131 h respec-
tive1y4 'i. Considerable intersubject varia-
tion in the half-life has also been
reported" 'i which was not as apparent in
this study (coefficient of variation for Day
22 = 15.7%) possibly because of our larger
numbers.
Steady-state is assumed to be close to 5
times the elimination t 1/). Using this to
estimate the time necessary to reach
steady-state in this study would have
given a period of 6 or 9 d, utilising our
calculated tlf, for Day 1 and Day 22 res-
pectively. Ravis et als. in their study, as-
sumed steady-state would be reached at
approximately 11 d. However, in this
study where dosing was continued over a
longer period of time, trough levels onlv




plasma pharmacokinetics to be described
adequately by a one-compartment open
model. Absorption rate constants showed
a 80-90% variation, but were within the
ranges found in other studies~ 5. The time
required to reach peak levels after oral
PHB, was between 2 to 4 h on Day 1)
Day 22, and Day 24. It would therefore
appear that the administration of food, to-
gether with the tablets, has little effect on
rate of absorption. However, if one com-
pares the extent of absorption using the
ACC values, there is a statistically sig-
nificant difference between administra-
tion with and without food. The lower
ADC on Day 24 is unlikely to be the
result of further enzyme induction and in-
creased clearance, as trough levels on Days
21, 22 and 24 are similar. Thus, it would
appear that the feeding of food together
with the tablets, reduces the extent of
PHB absorption by approximately 10%.
Continuous dosing with food therefore,
would be expected to produce serum level
profiles, on average 10% lower, than if
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give:l on an empty stomach. TJ.is is
probably of little clinical signific:mce~
especially if serum levels are :noni-
tared.
3) Side-effects of polyphagia, polydipsia~
sedation and ataxia are commonly ob-·
served in the first 2-9 d bur disappear
thereafter. This is probably due to
tolerance to the effects.
4) After initiation of therapy, dosing
should continue unchanged for 3
weeks (steady-state) before measuring
serum concentrations and adjusting
the dose accordingly.
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Fig. 2: Average trough serum pheno-
barbitone concentrations in
dogs (n = 10) over 24 days
1) An oral dose of j mg kg- 1 should give
average serum PHB concentrations of
65 JLmol e- 1 in adult dogs. Once daily
dosing may be adequate since rela-
tively small peak-trough fluctuations
were observed.
2) The dose may be given with food,
although the extent of absorption is
approximately 10% less than when
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